<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31562758</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1569-8041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
                <ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">mdz406</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdz406</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with metastatic pancreatic cancer (mPC) often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, Phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a poly(ADP-ribose) polymerase inhibitor, than placebo in patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and mPC whose disease had not progressed during first-line platinum-based chemotherapy. The prespecified HRQoL evaluation is reported here.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients were randomized to receive maintenance olaparib (300 mg bid; tablets) or placebo. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module at baseline, every 4 weeks until disease progression, at discontinuation, and 30 days after last dose. Scores ranged from 0 to 100; a ≥ 10-point change or difference between arms was considered clinically meaningful. Adjusted mean change from baseline was analysed using a mixed model for repeated measures. Time to sustained clinically meaningful deterioration (TSCMD) was analysed using a log-rank test.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 154 randomized patients, 89 of 92 olaparib-arm and 58 of 62 placebo-arm patients were included in HRQoL analyses. The adjusted mean change in Global Health Status (GHS) score from baseline was less than 10 points in both arms and there was no significant between-group difference (-2.47; 95% CI - 7.27, 2.33; P=0.31). Analysis of physical functioning scores showed a significant between-group difference (-4.45 points; 95% CI - 8.75, -0.16; P=0.04). There was no difference in TSCMD for olaparib versus placebo for GHS (P=0.25; HR 0.72; 95% CI 0.41, 1.27) or physical functioning (P=0.32; HR 1.38; 95%CI 0.73, 2.63).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HRQoL was preserved with maintenance olaparib treatment with no clinically meaningful difference compared with placebo. These results support the observed efficacy benefit of maintenance olaparib in patients with a gBRCAm and mPC.</AbstractText>
                <AbstractText Label="CLINCALTRIALS.GOV NUMBER" NlmCategory="UNASSIGNED">NCT02184195.</AbstractText>
                <CopyrightInformation>© The Author 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hammel</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hôpital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kindler</LastName>
                    <ForeName>H L</ForeName>
                    <Initials>HL</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Chicago, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reni</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cutsem</LastName>
                    <ForeName>E Van</ForeName>
                    <Initials>EV</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Macarulla</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hall</LastName>
                    <ForeName>M J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fox Chase Cancer Center, Philadelphia, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>J O</ForeName>
                    <Initials>JO</Initials>
                    <AffiliationInfo>
                        <Affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hochhauser</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>University College London Cancer Institute, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arnold</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Asklepios Tumorzentrum Hamburg Asklepios Klinik Altona, Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oh</LastName>
                    <ForeName>D-Y</ForeName>
                    <Initials>DY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reinacher-Schick</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tortora</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Azienda Ospedaliera Universitaria Integrata Verona, Verona and Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Algül</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Klinikum rechts der Isar, Comprehensive Cancer Center Munich-TUM and Technische Universität München, Munich, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Reilly</LastName>
                    <ForeName>E M</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McGuinness</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>AstraZeneca, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cui</LastName>
                    <ForeName>K Y</ForeName>
                    <Initials>KY</Initials>
                    <AffiliationInfo>
                        <Affiliation>AstraZeneca, Gaithersburg, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Joo</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoo</LastName>
                    <ForeName>H K</ForeName>
                    <Initials>HK</Initials>
                    <AffiliationInfo>
                        <Affiliation>AstraZeneca, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>AstraZeneca, Gaithersburg, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Golan</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Oncology Institute, Sheba Medical Center, Tel Aviv, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02184195</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Oncol</MedlineTA>
            <NlmUniqueID>9007735</NlmUniqueID>
            <ISSNLinking>0923-7534</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA</Keyword>
            <Keyword MajorTopicYN="N">Pancreatic cancer</Keyword>
            <Keyword MajorTopicYN="N">health-related quality of life</Keyword>
            <Keyword MajorTopicYN="N">metastatic</Keyword>
            <Keyword MajorTopicYN="N">olaparib</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31562758</ArticleId>
            <ArticleId IdType="pii">5575508</ArticleId>
            <ArticleId IdType="doi">10.1093/annonc/mdz406</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31553234</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-8301</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Future oncology (London, England)</Title>
                <ISOAbbreviation>Future Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline <i>BRCA</i> mutations: OPINION Phase IIIb study design.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.2217/fon-2019-0343</ELocationID>
            <Abstract>
                <AbstractText>The poly(ADP-ribose) polymerase inhibitor olaparib (Lynparza™) is approved for maintenance treatment of platinum-sensitive relapsed ovarian cancer. OPINION is a single-arm, open-label, multicenter, Phase IIIb study to assess the efficacy and safety of olaparib tablet maintenance therapy in women with high-grade serous or endometrioid platinum-sensitive relapsed ovarian cancer without a germline <i>BRCA1</i> or <i>BRCA2</i> mutation. Eligible patients should have received ≥2 prior lines of platinum-based chemotherapy and be in complete or partial response following their most recent course or have no evidence of disease. Patients will receive olaparib tablets (300 mg twice daily) until disease progression, unacceptable toxicity or another discontinuation criterion. The primary end point is investigator-assessed progression-free survival; secondary end points include progression-free survival according to tumor homologous recombination deficiency status. Clinical trial registration: NCT03402841.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Poveda</LastName>
                    <ForeName>Andres M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecologic Oncology, Initia Oncology, 46010 Valencia, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davidson</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>GMA Oncology TA, AstraZeneca, Cambridge, CB2 8PA, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blakeley</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>GMA Oncology TA, AstraZeneca, Cambridge, CB2 8PA, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Milner</LastName>
                    <ForeName>Alvin</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biometrics &amp; Information Sciences, AstraZeneca, Cambridge, CB2 8PA, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT03402841</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Future Oncol</MedlineTA>
            <NlmUniqueID>101256629</NlmUniqueID>
            <ISSNLinking>1479-6694</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA wild-type</Keyword>
            <Keyword MajorTopicYN="N">BRCAwt</Keyword>
            <Keyword MajorTopicYN="N">OPINION</Keyword>
            <Keyword MajorTopicYN="N">PARP inhibitor</Keyword>
            <Keyword MajorTopicYN="N">Phase IIIb</Keyword>
            <Keyword MajorTopicYN="N">maintenance treatment</Keyword>
            <Keyword MajorTopicYN="N">non-gBRCA mutated</Keyword>
            <Keyword MajorTopicYN="N">olaparib</Keyword>
            <Keyword MajorTopicYN="N">platinum-sensitive relapsed ovarian cancer</Keyword>
            <Keyword MajorTopicYN="N">progression-free survival</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31553234</ArticleId>
            <ArticleId IdType="doi">10.2217/fon-2019-0343</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31542591</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-1967</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>80</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>06</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer treatment reviews</Title>
                <ISOAbbreviation>Cancer Treat. Rev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>101895</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0305-7372(19)30111-2</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctrv.2019.101895</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Recent studies have shown that 4-20% of patients with PDAC have a germline BReast CAncer (gBRCA) genes 1 and 2 mutation (m). Because homologous recombination is impaired in patients with gBRCAm, some reports suggested that these tumors may be more sensitive to platinum compounds. Therefore, this systematic review and meta-analysis focused on benefit of patients with gBRCAm receiving a platinum-based chemotherapy (PtCh) compared with those treated with a non-platinum-based chemotherapy (NPtCh).</AbstractText>
                <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">The following electronic databases were searched from inception to May 12, 2018: PubMed (MEDLINE), EMBASE, and Cochrane Library. Abstracts from conferences were also reviewed for inclusion. Cohort, case-control and randomized studies of patients with PDAC and gBRCAm were eligible for inclusion if they provided data to compare patients receiving PtCh vs NPtCh. The primary endpoint was overall survival (OS) in the PtCh group vs the NPtCh group in patients with clinical stage III (locally advanced) or IV (metastatic) (CS III-IV) PDAC.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 112 studies identified, 6 were included (total of 108 patients); of these, 4 provided sufficient data for meta-analysis. Half of the patients were males, with a mean age ranging from 58 to 63 years. The OS in the 85 patients with CS III-IV PDAC was higher in the PtCh group (23.7 vs 12.2 months; mean difference of 10.21 months, 95% confidence interval [CI] 5.05-15.37; P &lt; 0.001; very low quality of evidence). PtCh was associated with a lower mortality (62.3 vs 87.5%; relative risk of 0.80, 95%CI 0.66-0.97; P = 0.021; very low quality of evidence).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study confirmed the hypothesis that patients with CS III-IV gBRCAm preferably benefit from a PtCh compared with NPtCh. However the very low quality of evidence should induce to be careful about the risk of potential biases. The generated hypothesis should be prospectively investigated in homogenous clinical settings.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rebelatto</LastName>
                    <ForeName>Taiane F</ForeName>
                    <Initials>TF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Falavigna</LastName>
                    <ForeName>Maicon</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute for Heath Technology Assessment, Postgraduate Program in Epidemiology, Porto Alegre, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pozzari</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spada</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cella</LastName>
                    <ForeName>Chiara A</ForeName>
                    <Initials>CA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laffi</LastName>
                    <ForeName>Alice</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pellicori</LastName>
                    <ForeName>Stefania</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fazio</LastName>
                    <ForeName>Nicola</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy. Electronic address: nicola.fazio@ieo.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Cancer Treat Rev</MedlineTA>
            <NlmUniqueID>7502030</NlmUniqueID>
            <ISSNLinking>0305-7372</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Germline BRCA mutation</Keyword>
            <Keyword MajorTopicYN="N">Pancreatic cancer</Keyword>
            <Keyword MajorTopicYN="N">Platinum-based chemotherapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31542591</ArticleId>
            <ArticleId IdType="pii">S0305-7372(19)30111-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ctrv.2019.101895</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31541380</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Risk-reducing mastectomy in BRCA carriers: survival is not the issue.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-019-05440-4</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Neven</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1434-9460</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium. Patrick.neven@uzleuven.be.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Punie</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wildiers</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Willers</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Ongeval</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Buggenhout</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Genetics, University Hospitals Leuven, Louvain, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Legius</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Centre and Leuven University Centre for Cancer Prevention (LUCK), University Hospitals Leuven, Louvain, Belgium.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Genetics, University Hospitals Leuven, Louvain, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31541380</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-019-05440-4</ArticleId>
            <ArticleId IdType="pii">10.1007/s10549-019-05440-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31538377</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-3599</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of genetic counseling</Title>
                <ISOAbbreviation>J Genet Couns</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Health professional and at-risk BRCA young adult perspectives about information needs: What does Gen Y need to know?</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jgc4.1167</ELocationID>
            <Abstract>
                <AbstractText>Young adults at risk of a hereditary condition require the provision of accurate information to make an informed decision about genetic testing and risk management options. At-risk young adults' (18- to 40-year olds) preferences for information and resources, and genetic-related health professionals' (GHPs) views on young adults' information needs, are largely unknown in the literature. This study aimed to clarify and compare the information needs of emerging (18- to 25-year olds) and early (26- to 40-year olds) adults. Resource preferences of young adults were also explored. Findings are drawn from two datasets: questionnaires and semi-structured interviews with at-risk young adults from BRCA1 or BRCA2 families (N = 32), and focus groups with GHPs (N = 73) working in Australian familial cancer clinics. Both datasets were analyzed using framework analysis. Emerging adults, particularly those who had not attended a clinic, wanted to know the rationale for genetic testing and basic genetic facts. Early adults were concerned about reproductive issues and cancer risk for future or current children. Information needs reported by young adults but not reported by GHPs include male cancer risk, finding reputable information, understanding test results (e.g., negative), and understanding risk terminology (e.g., lifetime cancer risk). Young adults' satisfaction with current information received was suboptimal, yet uptake of genetic-related resources was generally low. Getting information to this cohort remains a challenge for GHPs. Emerging adults showed a preference to obtain information through technologically-based formats (e.g., websites, social media), whereas early adults used a wider range of formats (e.g., websites, booklets). Awareness of and access to genetic information prior to genetic clinic attendance is needed. A review of the utility of current resources available for at-risk young adults would be helpful.</AbstractText>
                <CopyrightInformation>© 2019 National Society of Genetic Counselors.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Young</LastName>
                    <ForeName>Alison Luk</ForeName>
                    <Initials>AL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Science, School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Behavioral Sciences Unit Proudly Supported by the Kids with Cancer Foundation, Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Butow</LastName>
                    <ForeName>Phyllis N</ForeName>
                    <Initials>PN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Science, School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tucker</LastName>
                    <ForeName>Katherine M</ForeName>
                    <Initials>KM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prince of Wales Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Randwick, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Williams</LastName>
                    <ForeName>Rachel</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Prince of Wales Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Randwick, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Healey</LastName>
                    <ForeName>Emma</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wakefield</LastName>
                    <ForeName>Claire E</ForeName>
                    <Initials>CE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Behavioral Sciences Unit Proudly Supported by the Kids with Cancer Foundation, Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>APP1143767</GrantID>
                    <Agency>National Health and Medical Research Council of Australia</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <Agency>Kids with Cancer Foundation</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Genet Couns</MedlineTA>
            <NlmUniqueID>9206865</NlmUniqueID>
            <ISSNLinking>1059-7700</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">
BRCA1
</Keyword>
            <Keyword MajorTopicYN="N">
BRCA2
</Keyword>
            <Keyword MajorTopicYN="N">attitude to health</Keyword>
            <Keyword MajorTopicYN="N">attitudes</Keyword>
            <Keyword MajorTopicYN="N">beliefs</Keyword>
            <Keyword MajorTopicYN="N">communication</Keyword>
            <Keyword MajorTopicYN="N">genetic counseling</Keyword>
            <Keyword MajorTopicYN="N">genetic counselors</Keyword>
            <Keyword MajorTopicYN="N">genetic services</Keyword>
            <Keyword MajorTopicYN="N">genetic testing</Keyword>
            <Keyword MajorTopicYN="N">genetics</Keyword>
            <Keyword MajorTopicYN="N">health behavior</Keyword>
            <Keyword MajorTopicYN="N">health education</Keyword>
            <Keyword MajorTopicYN="N">health literacy</Keyword>
            <Keyword MajorTopicYN="N">health promotion</Keyword>
            <Keyword MajorTopicYN="N">hereditary breast and ovarian cancer syndrome</Keyword>
            <Keyword MajorTopicYN="N">information needs</Keyword>
            <Keyword MajorTopicYN="N">risk management</Keyword>
            <Keyword MajorTopicYN="N">young adult</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31538377</ArticleId>
            <ArticleId IdType="doi">10.1002/jgc4.1167</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31537627</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1472-4146</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical pathology</Title>
                <ISOAbbreviation>J. Clin. Pathol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">jclinpath-2019-206127</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1136/jclinpath-2019-206127</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">With the approval of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib for newly diagnosed, breast cancer gene <i>(BRCA)1/2</i> mutated, ovarian cancer women, the assessment of <i>BRCA1/2</i> tumour status will be shortly required at the time of diagnosis.</AbstractText>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate the feasibility of next-generation sequencing (NGS)-based BRCA tumour test on cytological specimens from ovarian cancer ascites.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated the <i>BRCA1/2</i> status on neoplastic ascites and corresponding tumour tissue of 11 patients with ovarian cancer, using the NGS 'Oncomine BRCA Research Assay'.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The NGS-based BRCA test on cytological samples had a success rate of 100%, with 11 of 11 concordant <i>BRCA1/2</i> results between ascites and tumour tissues analyses, including two wild type samples and nine cases harbouring somatic or germline variants.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">BRCA test may be performed on ovarian cancer ascites, reproducing <i>BRCA1/2</i> tumour status and representing a useful tool for clinical decision-making.</AbstractText>
                <CopyrightInformation>© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fumagalli</LastName>
                    <ForeName>Caterina</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology, IEO, European Institute of Oncology, IRCCS, Milano, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rappa</LastName>
                    <ForeName>Alessandra</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology, IEO, European Institute of Oncology, IRCCS, Milano, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Casadio</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology, IEO, European Institute of Oncology, IRCCS, Milano, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Betella</LastName>
                    <ForeName>Ilaria</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Surgery, IEO, European Institute of Oncology, IRCCS, Milano, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Colombo</LastName>
                    <ForeName>Nicoletta</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Medicine and Surgery, Università degli Studi di Milano-Bicocca, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barberis</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0943-4804</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology, IEO, European Institute of Oncology, IRCCS, Milano, Italy massimo.barberis@ieo.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guerini-Rocco</LastName>
                    <ForeName>Elena</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Clin Pathol</MedlineTA>
            <NlmUniqueID>0376601</NlmUniqueID>
            <ISSNLinking>0021-9746</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cytopathology</Keyword>
            <Keyword MajorTopicYN="N">molecular genetics</Keyword>
            <Keyword MajorTopicYN="N">ovarian tumour</Keyword>
        </KeywordList>
        <CoiStatement>Competing interests: CF received honoraria from Roche; EG-R received honoraria/advisory fee from Thermo Fisher Scientific, Roche, Novartis and AstraZeneca; and MB received honoraria from Thermo Fisher Scientific, Roche, BMS, MSD, and Biocartis.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31537627</ArticleId>
            <ArticleId IdType="pii">jclinpath-2019-206127</ArticleId>
            <ArticleId IdType="doi">10.1136/jclinpath-2019-206127</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31534547</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1838-7640</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>21</Issue>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Theranostics</Title>
                <ISOAbbreviation>Theranostics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6224-6238</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.36281</ELocationID>
            <Abstract>
                <AbstractText>Two recently approved PARP inhibitors provide an important new therapeutic option for patients with BRCA-mutated metastatic breast cancer. PARP inhibitors significantly prolong progression-free survival in patients, but conventional oral delivery of PARP inhibitors is hindered by limited bioavailability and off-target toxicities, thus compromising the therapeutic benefits and quality of life for patients. Here, we developed a new delivery system, in which the PARP inhibitor Talazoparib is encapsulated in the bilayer of a nano-liposome, to overcome these limitations. <b>Methods</b>: Nano-Talazoparib (NanoTLZ) was characterized both <i>in vitro</i> and <i>in vivo</i>. The therapeutic efficacy and toxicity of Nano-Talazoparib (NanoTLZ) were evaluated in BRCA-deficient mice. The regulation of NanoTLZ on gene transcription and immunomodulation were further investigated in spontaneous BRCA-deficient tumors. <b>Results</b>: NanoTLZ significantly (p&lt;0.05) prolonged the overall survival of BRCA-deficient mice compared to all of the other experimental groups, including saline control, empty nanoparticles, and free Talazoparib groups (oral and i.v.). Moreover, NanoTLZ was better tolerated than treatment with free Talazoparib, with no significant weight lost or alopecia as was observed with the free drug. After 5 doses, NanoTLZ altered the expression of over 140 genes and induced DNA damage, cell cycle arrest and inhibition of cell proliferation in the tumor. In addition, NanoTLZ favorably modulated immune cell populations <i>in vivo</i> and significantly (p&lt;0.05) decreased the percentage of myeloid derived suppressor cells in both the tumor and spleen compared to control groups. <b>Conclusions</b>: Our results demonstrate that delivering nanoformulated Talazoparib not only enhances treatment efficacy but also reduces off-target toxicities in BRCA-deficient mice; the same potential is predicted for patients with BRCA-deficient breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Di</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Michigan State University, East Lansing, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baldwin</LastName>
                    <ForeName>Paige</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Northeastern University, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leal</LastName>
                    <ForeName>Ana S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Michigan State University, East Lansing, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carapellucci</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Michigan State University, East Lansing, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sridhar</LastName>
                    <ForeName>Srinivas</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Northeastern University, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liby</LastName>
                    <ForeName>Karen T</ForeName>
                    <Initials>KT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Michigan State University, East Lansing, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Australia</Country>
            <MedlineTA>Theranostics</MedlineTA>
            <NlmUniqueID>101552395</NlmUniqueID>
            <ISSNLinking>1838-7640</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA-deficient breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Nanoparticle</Keyword>
            <Keyword MajorTopicYN="N">PARP inhibitor</Keyword>
            <Keyword MajorTopicYN="N">Talazoparib</Keyword>
            <Keyword MajorTopicYN="N">immunomodulation</Keyword>
        </KeywordList>
        <CoiStatement>Competing Interests: NanoTalazoparib is part of the subject matter and intellectual property in a patent application assigned to Northeastern University.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31534547</ArticleId>
            <ArticleId IdType="doi">10.7150/thno.36281</ArticleId>
            <ArticleId IdType="pii">thnov09p6224</ArticleId>
            <ArticleId IdType="pmc">PMC6735511</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31530924</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1476-4687</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>573</Volume>
                    <Issue>7774</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature</Title>
                <ISOAbbreviation>Nature</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cancer: more genetic BRCA testing for men.</ArticleTitle>
            <Pagination>
                <MedlinePgn>346</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/d41586-019-02775-2</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Marabelli</LastName>
                    <ForeName>Monica</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Calvello</LastName>
                    <ForeName>Mariarosaria</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonanni</LastName>
                    <ForeName>Bernardo</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016433">News</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nature</MedlineTA>
            <NlmUniqueID>0410462</NlmUniqueID>
            <ISSNLinking>0028-0836</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cancer</Keyword>
            <Keyword MajorTopicYN="N">Genetics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31530924</ArticleId>
            <ArticleId IdType="doi">10.1038/d41586-019-02775-2</ArticleId>
            <ArticleId IdType="pii">10.1038/d41586-019-02775-2</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31527132</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2159-8290</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer discovery</Title>
                <ISOAbbreviation>Cancer Discov</ISOAbbreviation>
            </Journal>
            <ArticleTitle>USPSTF Calls for More <i>BRCA</i> Screening.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-NB2019-105</ELocationID>
            <Abstract>
                <AbstractText>A recent U.S. Preventive Services Task Force statement reiterates the importance of screening women for <i>BRCA1/2</i> mutations and recommends that more women undergo risk-assessment screening, including those with a personal history of certain cancers and those with certain ancestries. Experts consider the recommendations a positive, if incremental, step that will likely have the biggest impact on community practices.</AbstractText>
                <CopyrightInformation>©2019 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Discov</MedlineTA>
            <NlmUniqueID>101561693</NlmUniqueID>
            <ISSNLinking>2159-8274</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31527132</ArticleId>
            <ArticleId IdType="pii">2159-8290.CD-NB2019-105</ArticleId>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-NB2019-105</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31521389</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-2157</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>05</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</Title>
                <ISOAbbreviation>Eur J Surg Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0748-7983(19)30662-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejso.2019.09.002</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the benefit of risk-reducing salpingo-oophorectomy (RRSO) by estimating the pathological positive rate of occult lesions, including serous tubal intraepithelial carcinoma (STIC) and occult cancers (OCCs).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">BRCA1/2 mutation carriers who underwent RRSO in a Chinese study center between 2014 and 2018 were included. A literature review was performed, followed by a meta-analysis of the literature to further validate the findings.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-four BRCA1/2 mutation carriers who underwent RRSO were identified; one patient (4.2%) had STIC, and one patient (4.2%) had occult fallopian tube cancer complicated by STIC. Thirty-four articles were ultimately included in the meta-analysis. Of the reported cases of OCC, 61.3% occurred in the fallopian tubes and 32.3% in the ovaries, and 81.5% were in the early stages. The estimated rate of overall pathological positive events was 5%. The estimated rates of overall STIC events and OCC were 1% and 3%, respectively. The rates of STIC and OCC were 1% and 3%, respectively, for BRCA1 mutation carriers and 1% and 1%, respectively, for BRCA2 mutation carriers. No significant difference was observed between the results of a routine examination of pathological sections and those of the Sectioning and Extensively Examining the Fimbriae (SEE-FIM) protocol.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study is the first report of RRSO results in China. In this systematic review, the positive rates of STIC or OCC after RRSO were no more than 3%, which are 200-fold higher than the risk of the general population. The use of a strict SEE-FIM protocol would likely increase positive results.</AbstractText>
                <CopyrightInformation>Copyright © 2019. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cheng</LastName>
                    <ForeName>Aoshuang</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, 100730, China. Electronic address: 371471648@qq.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, 100730, China. Electronic address: lileigh@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, 100730, China. Electronic address: wuming@pumch.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lang</LastName>
                    <ForeName>Jinghe</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Science, Beijing, 100730, China. Electronic address: langjh@vip.163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Surg Oncol</MedlineTA>
            <NlmUniqueID>8504356</NlmUniqueID>
            <ISSNLinking>0748-7983</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA mutation</Keyword>
            <Keyword MajorTopicYN="N">Meta-analysis</Keyword>
            <Keyword MajorTopicYN="N">Occult cancer</Keyword>
            <Keyword MajorTopicYN="N">Prophylactic oophorectomy</Keyword>
            <Keyword MajorTopicYN="N">Risk-reducing salpingo-oophorectomy</Keyword>
            <Keyword MajorTopicYN="N">Serous tubal intraepithelial carcinoma</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31521389</ArticleId>
            <ArticleId IdType="pii">S0748-7983(19)30662-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejso.2019.09.002</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31519911</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-1723</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>13</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature communications</Title>
                <ISOAbbreviation>Nat Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4182</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-12125-5</ELocationID>
            <Abstract>
                <AbstractText>Myoepithelial cells play key roles in normal mammary gland development and in limiting pre-invasive to invasive breast tumor progression, yet their differentiation and perturbation in ductal carcinoma in situ (DCIS) are poorly understood. Here, we investigated myoepithelial cells in normal breast tissues of BRCA1 and BRCA2 germline mutation carriers and in non-carrier controls, and in sporadic DCIS. We found that in the normal breast of non-carriers, myoepithelial cells frequently co-express the p63 and TCF7 transcription factors and that p63 and TCF7 show overlapping chromatin peaks associated with differentiated myoepithelium-specific genes. In contrast, in normal breast tissues of BRCA1 mutation carriers the frequency of p63<sup>+</sup>TCF7<sup>+</sup> myoepithelial cells is significantly decreased and p63 and TCF7 chromatin peaks do not overlap. These myoepithelial perturbations in normal breast tissues of BRCA1 germline mutation carriers may play a role in their higher risk of breast cancer. The fraction of p63<sup>+</sup>TCF7<sup>+</sup> myoepithelial cells is also significantly decreased in DCIS, which may be associated with invasive progression.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Lina</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Deciphera Pharmaceuticals, Waltham, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fassl</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hinohara</LastName>
                    <ForeName>Kunihiko</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Xintao</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harper</LastName>
                    <ForeName>Nicholas W</ForeName>
                    <Initials>NW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huh</LastName>
                    <ForeName>Sung Jin</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>ImmunoGen, Inc, Waltham, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bloushtain-Qimron</LastName>
                    <ForeName>Noga</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>EMEA Site Intelligence and Activation, Tel Aviv, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jovanović</LastName>
                    <ForeName>Bojana</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ekram</LastName>
                    <ForeName>Muhammad</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>WuXi NextCODE, Cambridge, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zi</LastName>
                    <ForeName>Xiaoyuan</ForeName>
                    <Initials>X</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2374-9001</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Second Military Medical University, Shanghai, 200433, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hines</LastName>
                    <ForeName>William C</ForeName>
                    <Initials>WC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>University of New Mexico School of Medicine, Albuquerque, NM, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alečković</LastName>
                    <ForeName>Maša</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5653-8502</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gil Del Alcazar</LastName>
                    <ForeName>Carlos</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caulfield</LastName>
                    <ForeName>Ryan J</ForeName>
                    <Initials>RJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonal</LastName>
                    <ForeName>Dennis M</ForeName>
                    <Initials>DM</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7805-1209</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Quang-De</ForeName>
                    <Initials>QD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Merino</LastName>
                    <ForeName>Vanessa F</ForeName>
                    <Initials>VF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choudhury</LastName>
                    <ForeName>Sibgat</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Metamark Genetics Inc, Worcester, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ethington</LastName>
                    <ForeName>Gabrielle</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Baylor-Charles A. Sammons Cancer Center, Dallas, TX, 75246, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Panos</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Baylor-Charles A. Sammons Cancer Center, Dallas, TX, 75246, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grant</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Baylor-Charles A. Sammons Cancer Center, Dallas, TX, 75246, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Herlihy</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Baylor-Charles A. Sammons Cancer Center, Dallas, TX, 75246, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Au</LastName>
                    <ForeName>Alfred</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 94143, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosson</LastName>
                    <ForeName>Gedge D</ForeName>
                    <Initials>GD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Argani</LastName>
                    <ForeName>Pedram</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Richardson</LastName>
                    <ForeName>Andrea L</ForeName>
                    <Initials>AL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins Medical Institutions, Baltimore, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dillon</LastName>
                    <ForeName>Deborah</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Allred</LastName>
                    <ForeName>D Craig</ForeName>
                    <Initials>DC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Washington University School of Medicine, St. Louis, MO, 63110, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Babski</LastName>
                    <ForeName>Kirsten</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sutter Roseville Medical Center, Roseville, CA, 95661, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Elizabeth Min Hui</ForeName>
                    <Initials>EMH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sutter Roseville Medical Center, Roseville, CA, 95661, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cancer Treatment Centers of America, Atlanta, GA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McDonnell</LastName>
                    <ForeName>Charles H</ForeName>
                    <Initials>CH</Initials>
                    <Suffix>3rd</Suffix>
                    <AffiliationInfo>
                        <Affiliation>Sutter Roseville Medical Center, Roseville, CA, 95661, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wagner</LastName>
                    <ForeName>Jon</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sutter Roseville Medical Center, Roseville, CA, 95661, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rowberry</LastName>
                    <ForeName>Ron</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sutter Roseville Medical Center, Roseville, CA, 95661, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bobolis</LastName>
                    <ForeName>Kristie</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sutter Roseville Medical Center, Roseville, CA, 95661, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kleer</LastName>
                    <ForeName>Celina G</ForeName>
                    <Initials>CG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hwang</LastName>
                    <ForeName>E Shelley</ForeName>
                    <Initials>ES</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 94143, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Duke University, Durham, NC, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blum</LastName>
                    <ForeName>Joanne L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Baylor-Charles A. Sammons Cancer Center, Dallas, TX, 75246, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cristea</LastName>
                    <ForeName>Simona</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Data Science, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Harvard T. H. Chan School of Public Health Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University Cambridge, Cambridge, MA, 02138, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sicinski</LastName>
                    <ForeName>Piotr</ForeName>
                    <Initials>P</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8859-5234</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fan</LastName>
                    <ForeName>Rong</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7805-8059</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Long</LastName>
                    <ForeName>Henry W</ForeName>
                    <Initials>HW</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6849-6629</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sukumar</LastName>
                    <ForeName>Saraswati</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>So Yeon</ForeName>
                    <Initials>SY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garber</LastName>
                    <ForeName>Judy E</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bissell</LastName>
                    <ForeName>Mina</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5841-4423</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yao</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>MD Anderson Cancer Center, Houston, TX, 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Polyak</LastName>
                    <ForeName>Kornelia</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5964-0382</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA. Kornelia_Polyak@dfci.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA. Kornelia_Polyak@dfci.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA. Kornelia_Polyak@dfci.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. Kornelia_Polyak@dfci.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Harvard Stem Cell Institute, Cambridge, MA, 02138, USA. Kornelia_Polyak@dfci.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 CA125577</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA202634</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R35CA197623</GrantID>
                    <Agency>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>U01 CA143233</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 CA080111</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA107469</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R35 CA197623</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CA080111</GrantID>
                    <Agency>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>CA202634</GrantID>
                    <Agency>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>CA143233</GrantID>
                    <Agency>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Commun</MedlineTA>
            <NlmUniqueID>101528555</NlmUniqueID>
            <ISSNLinking>2041-1723</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31519911</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-019-12125-5</ArticleId>
            <ArticleId IdType="pii">10.1038/s41467-019-12125-5</ArticleId>
            <ArticleId IdType="pmc">PMC6744561</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">31516602</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1792-1074</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>18</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Oncology letters</Title>
                <ISOAbbreviation>Oncol Lett</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8<sup>+</sup> T cells compared with women with BRCA wild-type disease during the early disease course.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3914-3924</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3892/ol.2019.10731</ELocationID>
            <Abstract>
                <AbstractText>Immunosuppressive myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) are associated with immunologic tolerance and poor prognosis in ovarian cancer (OvCa). We hypothesized that women with germline BRCA1 and BRCA2 mutation-associated (gBRCAm) OvCa would have fewer circulating immunosuppressive immune cells compared to those with BRCA wild-type (BRCAwt) disease during their early disease course (&lt;5 years post-diagnosis) where gBRCAm is a favorable prognostic factor. We collected and viably froze peripheral blood mononuclear cells (PBMCs) from patients with recurrent OvCa olaparib clinical trials (NCT01445418/NCT01237067). Immune subset analyses were performed using flow cytometry for Tregs, exhausted CD8<sup>+</sup> T cells, monocytes and MDSCs. Functional marker expression, including cytotoxic T lymphocyte-associated protein 4 (CTLA-4), T cell immunoglobulin and mucin domain 3 (TIM-3) and programmed cell death protein 1 (PD-1) was evaluated. Data were analyzed using FlowJo. Pretreatment PBMCs were collected from 41 patients (16 gBRCAm/25 BRCAwt). The percentage of MDSCs among viable CD45<sup>+</sup> PBMC was lower in gBRCAm OvCa compared with BRCAwt OvCa (median 0.565 vs. 0.93%, P=0.0086) but this difference was not seen in those women &gt;5 years post-diagnosis. CD8<sup>+</sup> T cells among viable CD45<sup>+</sup> PBMCs and CTLA-4<sup>+</sup>/CD8<sup>+</sup> T cells were higher in gBRCAm carriers than patients with BRCAwt, in particular for those &lt;5 years post-diagnosis (median 20.4 vs. 9.78%, P=0.031 and median MFI 0.19 vs. 0.22, P=0.0074, respectively). TIM-3 expression on Tregs was associated with poor progression-free survival, independent of gBRCAm status (P&lt;0.001). Our pilot data suggested that patients with gBRCAm OvCa may have fewer circulating MDSCs but higher CD8<sup>+</sup> T cells in PBMCs during their early disease course. This may contribute to the observed survival benefit for these women in their first post-diagnosis decade.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jung-Min</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Botesteanu</LastName>
                    <ForeName>Dana-Adriana</ForeName>
                    <Initials>DA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomita</LastName>
                    <ForeName>Yusuke</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuno</LastName>
                    <ForeName>Akira</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Min-Jung</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kohn</LastName>
                    <ForeName>Elise C</ForeName>
                    <Initials>EC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Annunziata</LastName>
                    <ForeName>Christina M</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matulonis</LastName>
                    <ForeName>Ursula</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>MacDonald</LastName>
                    <ForeName>Lauren A</ForeName>
                    <Initials>LA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nair</LastName>
                    <ForeName>Jayakumar R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Macneill</LastName>
                    <ForeName>Kimberley M</ForeName>
                    <Initials>KM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trepel</LastName>
                    <ForeName>Jane B</ForeName>
                    <Initials>JB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Oncol Lett</MedlineTA>
            <NlmUniqueID>101531236</NlmUniqueID>
            <ISSNLinking>1792-1074</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">BRCA</Keyword>
            <Keyword MajorTopicYN="Y">immune cells</Keyword>
            <Keyword MajorTopicYN="Y">immune system</Keyword>
            <Keyword MajorTopicYN="Y">ovarian cancer</Keyword>
            <Keyword MajorTopicYN="Y">survival benefit</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31516602</ArticleId>
            <ArticleId IdType="doi">10.3892/ol.2019.10731</ArticleId>
            <ArticleId IdType="pii">OL-0-0-10731</ArticleId>
            <ArticleId IdType="pmc">PMC6732977</ArticleId>
        </ArticleIdList>
        <?pmcsd?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31507061</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-0528</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BJOG : an international journal of obstetrics and gynaecology</Title>
                <ISOAbbreviation>BJOG</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/1471-0528.15905</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Unselected population-based BRCA testing provides the opportunity to apply genomics on a population-scale to maximise primary prevention for breast-and-ovarian cancer. We compare long-term outcomes of population-based and family-history (FH)/clinical-criteria-based BRCA testing on psychological health and quality of life.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">Randomised controlled trial (RCT) (ISRCTN73338115) GCaPPS, with two-arms: (i) population-screening (PS); (ii) FH/clinical-criteria-based testing.</AbstractText>
                <AbstractText Label="SETTING" NlmCategory="METHODS">North London Ashkenazi-Jewish (AJ) population.</AbstractText>
                <AbstractText Label="POPULATION/SAMPLE" NlmCategory="METHODS">AJ women/men.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Population-based RCT (1:1). Participants were recruited through self-referral, following pre-test genetic counselling from the North London AJ population.</AbstractText>
                <AbstractText Label="INCLUSION CRITERIA" NlmCategory="METHODS">AJ women/men &gt;18 years old; exclusion-criteria: prior BRCA testing or first-degree relatives of BRCA-carriers.</AbstractText>
                <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Genetic testing for three Jewish BRCA founder-mutations: 185delAG (c.68_69delAG), 5382insC (c.5266dupC) and 6174delT (c.5946delT), for (i) all participants in PS arm; (ii) those fulfilling FH/clinical criteria in FH arm. Linear mixed models and appropriate contrast tests were used to analyse the impact of BRCA testing on psychological and quality-of-life outcomes over 3 years.</AbstractText>
                <AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Validated questionnaires (HADS/MICRA/HAI/SF12) used to analyse psychological wellbeing/quality-of-life outcomes at baseline/1-year/2-year/3-year follow up.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In all, 1034 individuals (691 women, 343 men) were randomised to PS (n = 530) or FH (n = 504) arms. There was a statistically significant decrease in anxiety (P = 0.046) and total anxiety-&amp;-depression scores (P = 0.0.012) in the PS arm compared with the FH arm over 3 years. No significant difference was observed between the FH and PS arms for depression, health-anxiety, distress, uncertainty, quality-of-life or experience scores associated with BRCA testing. Contrast tests showed a decrease in anxiety (P = 0.018), health-anxiety (P &lt; 0.0005) and quality-of-life (P = 0.004) scores in both PS and FH groups over time. Eighteen of 30 (60%) BRCA carriers identified did not fulfil clinical criteria for BRCA testing. Total BRCA prevalence was 2.9% (95% CI 1.97-4.12%), BRCA1 prevalence was 1.55% (95% CI 0.89-2.5%) and BRCA2 prevalence was 1.35% (95% CI 0.74-2.26%).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Population-based AJ BRCA testing does not adversely affect long-term psychological wellbeing or quality-of-life, decreases anxiety and could identify up to 150% additional BRCA carriers.</AbstractText>
                <AbstractText Label="TWEETABLE ABSTRACT" NlmCategory="UNASSIGNED">Population BRCA testing in Ashkenazi Jews reduces anxiety and does not adversely affect psychological health or quality of life.</AbstractText>
                <CopyrightInformation>© 2019 Royal College of Obstetricians and Gynaecologists.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Manchanda</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-3381-5057</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Wolfson Institute of Preventive Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynaecological Oncology, St Bartholomew's Hospital, London, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>MRC Clinical Trials Unit, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burnell</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC Clinical Trials Unit, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gaba</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Wolfson Institute of Preventive Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Desai</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC Clinical Trials Unit, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wardle</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Behavioural Sciences Unit, Department of Epidemiology and Public Health, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gessler</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC Clinical Trials Unit, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Side</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Hospital Southampton NHS Foundation Trust, Southampton, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanderson</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Behavioural Sciences Unit, Department of Epidemiology and Public Health, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loggenberg</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>North East Thames Regional Genetics Unit, Department of Clinical Genetics, Great Ormond Street Hospital, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brady</LastName>
                    <ForeName>A F</ForeName>
                    <Initials>AF</Initials>
                    <AffiliationInfo>
                        <Affiliation>North West Thames Regional Genetics Service, Northwick Park Hospital, Harrow, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dorkins</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>St Peter's College, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wallis</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chapman</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>West Midlands Regional Genetics Service, Department of Clinical Genetics, Birmingham Women's NHS Foundation Trust, Birmingham, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobs</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Genetics, Guy's Hospital, London, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>University of Technology Sydney, Sydney, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Legood</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beller</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynaecology, Shaare Zedek Medical Centre, Jerusalem, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomlinson</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Menon</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>MRC Clinical Trials Unit, University College London, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobs</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of New South Wales, UNSW Sydney, Sydney, NSW, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <Agency>'The Eve Appeal' charity</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BJOG</MedlineTA>
            <NlmUniqueID>100935741</NlmUniqueID>
            <ISSNLinking>1470-0328</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">
BRCA1
</Keyword>
            <Keyword MajorTopicYN="N">
BRCA2
</Keyword>
            <Keyword MajorTopicYN="N">Ashkenazi Jews</Keyword>
            <Keyword MajorTopicYN="N">genetic testing</Keyword>
            <Keyword MajorTopicYN="N">population testing</Keyword>
            <Keyword MajorTopicYN="N">psychological</Keyword>
            <Keyword MajorTopicYN="N">quality-of-life</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31507061</ArticleId>
            <ArticleId IdType="doi">10.1111/1471-0528.15905</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31492746</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1078-0432</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>06</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Germline <i>BRCA</i>-associated Endometrial Carcinoma is a Distinct Clinicopathologic Entity.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">clincanres.0848.2019</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-19-0848</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Whether endometrial cancer (EC) should be considered part of the <i>gBRCA1/2-</i>associated Hereditary Breast and Ovarian Cancer (HBOC)-syndrome is topic of debate. We sought to assess whether ECs occurring in <i>gBRCA</i> carriers are enriched for clinicopathologic and molecular characteristics, thereby supporting a causal relationship.</AbstractText>
                <AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">Thirty-eight <i>gBRCA</i> carriers that developed EC were selected from the nationwide cohort study on Hereditary Breast and Ovarian Cancer in the Netherlands (HEBON), and these were supplemented with four institutional cases. Tumor tissue was retrieved via PALGA (Dutch Pathology Registry). Nineteen morphologic features were scored and histotype was determined by three expert gynecologic pathologists, blinded for molecular analyses (UCM-OncoPlus Assay including 1213 genes). ECs with LOH of the <i>g<i>BRCA-</i></i> wildtype allele (<i>gBRCA</i>/LOHpos) were defined &quot;<i>g<i>BRCA</i></i> -associated&quot;, those without LOH (<i>gBRCA</i>/LOHneg) were defined 'sporadic'.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">LOH could be assessed for 40 ECs (30 <i>g<i>BRCA1,</i></i> 10 <i>g<i>BRCA2</i></i> ), of which 60% were <i>gBRCA/</i>LOHpos. <i>gBRCA/</i>LOHpos ECs were more frequently of non-endometrioid (58%, <i>P=</i>0.001) and grade 3 histology (79%, <i>P</i>&lt;0.001). All but two were in the <i>TP53-mutated TCGA-</i>subgroup (91.7%, <i>P&lt;</i>0.001). In contrast, <i>gBRCA/</i>LOHneg ECs were mainly grade 1 endometrioid EC (94%) and showed a more heterogeneous distribution of TCGA-molecular subgroups: <i>POLE-mutated</i> (6.3%), MSI-high (25%), NSMP (62.5%) and <i>TP53-mutated</i> (6.3%).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We provide novel evidence in favour of EC being part of the <i>gBRCA</i>-associated HBOC-syndrome. <i>gBRCA</i>-associated ECs are enriched for EC subtypes associated with unfavourable clinical outcome. These findings have profound therapeutic consequences as these patients may benefit from treatment strategies such as PARP-inhibitors. Additionally, it should influence counselling and surveillance of <i>gBRCA</i> carriers.</AbstractText>
                <CopyrightInformation>Copyright ©2019, American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>de Jonge</LastName>
                    <ForeName>Marthe M</ForeName>
                    <Initials>MM</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-6578-7225</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Pathology, Leiden University Medical Center.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ritterhouse</LastName>
                    <ForeName>Lauren L</ForeName>
                    <Initials>LL</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-7655-630X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Pathology, Massachusetts General Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Kroon</LastName>
                    <ForeName>Cornelis D</ForeName>
                    <Initials>CD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gynecology, Leiden University Medical Center.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vreeswijk</LastName>
                    <ForeName>Maaike P G</ForeName>
                    <Initials>MPG</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-4068-9271</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Human Genetics, Leiden University Medical Center.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Segal</LastName>
                    <ForeName>Jeremy P</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Divison of Genomic and Molecular Pathology, Department of Pathology, University of Chicago.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Puranik</LastName>
                    <ForeName>Rutika</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Pathology, University of Chicago.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Study</LastName>
                    <ForeName>Hebon</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Psychosocial Research and Epidemiology, Netherlands Cancer Institute.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hollema</LastName>
                    <ForeName>Harry</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, University Medical Center Groningen.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rookus</LastName>
                    <ForeName>Matti A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, The Netherlands Cancer Institute.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Asperen</LastName>
                    <ForeName>Christi J</ForeName>
                    <Initials>CJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Genetics, Dept. of Clinical Genetics, Leiden University Medical Center.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Leeuwen</LastName>
                    <ForeName>Flora E</ForeName>
                    <Initials>FE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Epidemiology, Netherlands Cancer Institute.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smit</LastName>
                    <ForeName>Vincent T H B M</ForeName>
                    <Initials>VTHBM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Leiden University Medical Center.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howitt</LastName>
                    <ForeName>Brooke E</ForeName>
                    <Initials>BE</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-0309-6680</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Stanford University Medical Center.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bosse</LastName>
                    <ForeName>Tjalling</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology, Leiden University Medical Center t.bosse@lumc.nl.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Cancer Res</MedlineTA>
            <NlmUniqueID>9502500</NlmUniqueID>
            <ISSNLinking>1078-0432</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31492746</ArticleId>
            <ArticleId IdType="pii">1078-0432.CCR-19-0848</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-0848</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">31489114</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>49</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Vascular endothelium function among male carriers of BRCA 1&amp;2 germline mutation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5041-5051</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.27118</ELocationID>
            <Abstract>
                <AbstractText><b>Background:</b> Breast cancer susceptibility genes 1&amp;2 (BRCA1&amp;2) mutations hinder DNA-repair. Germline mutations in these genes are known to cause cancer; however, they may have other consequences. In this study we evaluated for the first time, the effect of the BRCA mutations on the vascular endothelium of young healthy males. <b>Results:</b> The study included 82 participants (53 BRCA mutation positive-carriers and 29 negative-carriers). Subjects mean age was 40. There were no significant differences in the baseline characteristics of the two groups. BRCA-carriers had significantly higher levels of EPCs (fraction of CD34+/VEGF or CD133+/VEGF positive-cells) compared to non-carriers of the mutation (median 6.78[1.96,14.48]% vs. 1.46[0.65,6.18]%, <i>p</i> &lt; 0.001, and median 7.17[1.70,16.69]% vs. 1.54[0.85,5.10]%, <i>p</i> &lt; 0.001, respectively). This difference remained consistent after multivariate adjustment. We did not identify differences in endothelial function, endothelial damage markers and EPCs activity between the two groups. <b>Methods:</b> This was a prospective cohort study to test the association between BRCA status and possible endothelial alterations. The Study population included males, 18-50 years, with no cardiovascular morbidity, who were referred for BRCA screening. We tested the endothelial system by: Endothelial progenitor cells (EPC) production, endothelial function (EndoPAT2000), endothelial damage and related hormonal levels. We stratified the cohort by germline BRCA status and compared measurements between BRCA mutation positive- and negative-carriers. <b>Conclusions:</b> Male BRCA1&amp;2 mutation positive-carriers had increased level of EPCs which may reflect a subclinical accumulative endothelial damage. These novel findings suggest that the effect of mutations in BRCA is not limited to increased cancer risk, but may affect the cardiovascular system.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Witberg</LastName>
                    <ForeName>Guy</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Lev</LastName>
                    <ForeName>Eli</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Assuta Ashdod University Hospital, Ashdod, Israel.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Medicine, Ben Gurion University, Be'er Sheva, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ber</LastName>
                    <ForeName>Yaara</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tabachnik</LastName>
                    <ForeName>Tzlil</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sela</LastName>
                    <ForeName>Sivan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belo</LastName>
                    <ForeName>Ira</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leshem-Lev</LastName>
                    <ForeName>Dorit</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Margel</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Rabin Medical Center, Petach Tikva, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA</Keyword>
            <Keyword MajorTopicYN="N">DNA repair</Keyword>
            <Keyword MajorTopicYN="N">cardiovascular system</Keyword>
            <Keyword MajorTopicYN="N">endothelial progenitor cells</Keyword>
            <Keyword MajorTopicYN="N">vascular endothelium damage</Keyword>
        </KeywordList>
        <CoiStatement>CONFLICTS OF INTEREST Dr. Margel reports grants and personal fees from Ferring Pharmaceuticals, grants from The Israeli National Institute for Health Policy, outside the submitted work. Other authors have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31489114</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.27118</ArticleId>
            <ArticleId IdType="pii">27118</ArticleId>
            <ArticleId IdType="pmc">PMC6707947</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31488070</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>05</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC medical genetics</Title>
                <ISOAbbreviation>BMC Med. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>BRCA mutations in a cohort of Iraqi patients presenting to a tertiary referral center.</ArticleTitle>
            <Pagination>
                <MedlinePgn>154</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12881-019-0885-9</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Unique pathogenic mutations in BRCA1 and 2 genes have been reported in different populations of patients originating from the Middle East region. Limited data are available for the Iraqi population. For many reasons a large number of Iraqi patients present to Lebanon for medical care. This is the first report of BRCA full gene sequencing conducted in a cohort of high-risk patients originating from Iraq.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective review of Iraqi patients diagnosed with breast or ovarian cancer referred for BRCA mutation testing at the American University of Beirut from January 2012 to October 2018.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 42 Iraqi women who underwent genetic testing at our institution, 3 BRCA pathogenic variants were found. Two mutations in BRCA1 c.224_227delAAAG and c.5431C &gt; T and one mutation in BRCA2 c.5576_5579delTTAA were identified. Three other patients had sequence changes considered as variants of undetermined significance.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this cohort of high-risk patients, one out of the three pathogenic BRCA variants detected has not previously been reported in the Middle Eastern population. Further studies are required to delineate the spectrum of BRCA mutations in the Iraqi population.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Farra</LastName>
                    <ForeName>Chantal</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Genetics Unit, Pathology Department, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dagher</LastName>
                    <ForeName>Christelle</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamadeh</LastName>
                    <ForeName>Lama</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Genetics Unit, Pathology Department, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>El Saghir</LastName>
                    <ForeName>Nagi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mukherji</LastName>
                    <ForeName>Deborah</ForeName>
                    <Initials>D</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0192-5828</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. dm25@aub.edu.lb.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Med Genet</MedlineTA>
            <NlmUniqueID>100968552</NlmUniqueID>
            <ISSNLinking>1471-2350</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA1</Keyword>
            <Keyword MajorTopicYN="N">BRCA2</Keyword>
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Iraq</Keyword>
            <Keyword MajorTopicYN="N">Middle East</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31488070</ArticleId>
            <ArticleId IdType="doi">10.1186/s12881-019-0885-9</ArticleId>
            <ArticleId IdType="pii">10.1186/s12881-019-0885-9</ArticleId>
            <ArticleId IdType="pmc">PMC6728935</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31478804</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-1315</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>03</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Radiology</Title>
                <ISOAbbreviation>Radiology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Breast Cancer Screening in <i>BRCA</i> Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.</ArticleTitle>
            <Pagination>
                <MedlinePgn>191306</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1148/radiol.2019191306</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Colin</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0001-7533-3692</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Breast Imaging, Hospices Civils de Lyon, Centre Hospitalier Femme Mère Enfant, 59 Boulevard Pinel, 69677 Bron, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doutriaux-Dumoulin</LastName>
                    <ForeName>Isabelle</ForeName>
                    <Initials>I</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0003-4524-7077</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Radiology</MedlineTA>
            <NlmUniqueID>0401260</NlmUniqueID>
            <ISSNLinking>0033-8419</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31478804</ArticleId>
            <ArticleId IdType="doi">10.1148/radiol.2019191306</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31468137</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0843</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer chemotherapy and pharmacology</Title>
                <ISOAbbreviation>Cancer Chemother. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00280-019-03930-2</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Veliparib, a poly(ADP-ribose)-polymerase (PARP) 1 and 2 enzyme inhibitor, was administered at 120 mg twice daily (BID) for 7 days in a 21-day cycle with carboplatin/paclitaxel in the Phase 2 BROCADE study in patients with BRCA-deficient recurrent or metastatic breast cancer, a dose based on Phase 1 results. Population pharmacokinetic (PK) and exposure-response analyses were undertaken to retrospectively evaluate whether an optimal dose was used in BROCADE.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A population PK analysis was performed using data from 168 patients in BROCADE along with data from 288 subjects in another 5 studies. The relationship between veliparib exposure and efficacy variables (including progression-free survival [PFS] and objective response rate [ORR]) and safety variables (selected grade 3 or greater hematological adverse events) were analyzed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Veliparib PK parameters in BROCADE were comparable to the previous studies. Creatinine clearance on veliparib apparent clearance and lean body weight on veliparib apparent volume of distribution were identified as covariates. A trend of better efficacy (PFS and ORR) in the veliparib arm compared to placebo was observed. However, veliparib exposure-efficacy response was relatively flat with higher veliparib exposures not showing better efficacy. No exposure-response relationship was observed in grade 3 or greater hematological toxicities (anemia, neutropenia, leukopenia, and thrombocytopenia).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The exposure-response analysis suggested that intermittent 7-day veliparib 120 mg BID dosing in a 21-day cycle provided additional efficacy without meaningfully impacting the safety and tolerability when co-administered with carboplatin and paclitaxel in patients with BRCA-deficient breast cancer. A higher dose of veliparib is unlikely to provide greater benefit in this combination in patients with BRCA-deficient recurrent or metastatic breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nuthalapati</LastName>
                    <ForeName>Silpa</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology and Pharmacometrics, Department R4PK, AbbVie Inc, Building AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stodtmann</LastName>
                    <ForeName>Sven</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH &amp; Co. KG, Ludwigshafen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shepherd</LastName>
                    <ForeName>Stacie Peacock</ForeName>
                    <Initials>SP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncology Development, AbbVie Inc, North Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ratajczak</LastName>
                    <ForeName>Christine K</ForeName>
                    <Initials>CK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncology Development, AbbVie Inc, North Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mensing</LastName>
                    <ForeName>Sven</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH &amp; Co. KG, Ludwigshafen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Menon</LastName>
                    <ForeName>Rajeev</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology and Pharmacometrics, Department R4PK, AbbVie Inc, Building AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiong</LastName>
                    <ForeName>Hao</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology and Pharmacometrics, Department R4PK, AbbVie Inc, Building AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA. hao.xiong@abbvie.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Cancer Chemother Pharmacol</MedlineTA>
            <NlmUniqueID>7806519</NlmUniqueID>
            <ISSNLinking>0344-5704</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Carboplatin</Keyword>
            <Keyword MajorTopicYN="N">Exposure–response</Keyword>
            <Keyword MajorTopicYN="N">Paclitaxel</Keyword>
            <Keyword MajorTopicYN="N">Veliparib</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31468137</ArticleId>
            <ArticleId IdType="doi">10.1007/s00280-019-03930-2</ArticleId>
            <ArticleId IdType="pii">10.1007/s00280-019-03930-2</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">31467964</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2352-5789</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>29</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gynecologic oncology reports</Title>
                <ISOAbbreviation>Gynecol Oncol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline <i>BRCA</i> mutations.</ArticleTitle>
            <Pagination>
                <MedlinePgn>113-117</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gore.2019.08.001</ELocationID>
            <Abstract>
                <AbstractText>The objectives of this study were to describe the patterns and duration of primary and recurrent treatment in patients with ovarian cancer (OC) harboring germline <i>BRCA1</i> and <i>BRCA2</i> (<i>BRCA</i>) mutations. A retrospective review of <i>BRCA</i> mutation carriers with advanced, high-grade OC diagnosed between 2004 and 2014 with at least 3 years of follow-up (or until death) was undertaken. Descriptive statistics were calculated and a Swimmer's Plot used to depict disease course. Forty <i>BRCA</i> mutation carriers (26 <i>BRCA1</i>, 14 <i>BRCA2</i>) were identified. Mean age was 54 (range 32-77). All had cytoreductive surgery and received platinum chemotherapy. Median platinum-free interval was 11.9 months (IQR 3.6-21.9). Among 28 patients who recurred, median number of treatment lines was 4 (IQR 3-6), with a median of 2 (IQR 2-3) platinum lines. On average, patients who recurred spent 32% (IQR 20-43%) of their time after diagnosis receiving cytotoxic chemotherapy and 54% (IQR 42-67%) of the time on some cancer-directed therapy, including maintenance. Median overall survival was 79.1 months from diagnosis and 25.4 months after first recurrence. In conclusion, beyond first-line therapy, there was treatment and outcome heterogeneity for <i>BRCA</i>-mutated OC. After OC diagnosis, patients spent close to half their life on treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jorge</LastName>
                    <ForeName>Soledad</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swisher</LastName>
                    <ForeName>Elizabeth M</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Norquist</LastName>
                    <ForeName>Barbara M</ForeName>
                    <Initials>BM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pennington</LastName>
                    <ForeName>Kathryn P</ForeName>
                    <Initials>KP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gray</LastName>
                    <ForeName>Heidi J</ForeName>
                    <Initials>HJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Urban</LastName>
                    <ForeName>Renata R</ForeName>
                    <Initials>RR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garcia</LastName>
                    <ForeName>Rochelle L</ForeName>
                    <Initials>RL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doll</LastName>
                    <ForeName>Kemi M</ForeName>
                    <Initials>KM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Gynecol Oncol Rep</MedlineTA>
            <NlmUniqueID>101652231</NlmUniqueID>
            <ISSNLinking>2352-5789</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA1 and BRCA2 mutations</Keyword>
            <Keyword MajorTopicYN="N">Disease course</Keyword>
            <Keyword MajorTopicYN="N">Long-term</Keyword>
            <Keyword MajorTopicYN="N">Ovarian cancer</Keyword>
            <Keyword MajorTopicYN="N">Treatment</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31467964</ArticleId>
            <ArticleId IdType="doi">10.1016/j.gore.2019.08.001</ArticleId>
            <ArticleId IdType="pii">S2352-5789(19)30076-1</ArticleId>
            <ArticleId IdType="pmc">PMC6710556</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">31467961</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2352-5789</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>29</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gynecologic oncology reports</Title>
                <ISOAbbreviation>Gynecol Oncol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle><i>BRCA</i> mutation in high grade epithelial ovarian cancers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>102-105</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gore.2019.07.007</ELocationID>
            <Abstract>
                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">To identify the frequency of <i>BRCA</i> mutation in patients with high grade epithelial ovarian cancer (EOC).</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">Patients with EOC included fallopian tube cancer or peritoneal cancer with high grade serous or high grade endometrioid were recruited. <i>BRCA1</i> and <i>BRCA2</i> mutations were tested and analyzed by next generation sequencing system.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 87 patients were recruited; majority of them (88.5%) were EOC, 5.7% fallopian tube cancer, 4.6% peritoneal cancer, and 1.1% synchronous primary ovarian and endometrial cancer. Seventy-four patients (85.1%) had high grade serous carcinoma and 13 patients (14.9%) had high grade endometrioid carcinoma. Germline <i>BRCA</i> mutation was detected in 19 patients (21.8%); 14 patients (16.1%) had <i>BRCA1</i> mutation and 5 patients (5.7%) had <i>BRCA2</i> mutation. All <i>BRCA</i> mutations were found in patients with high grade serous carcinoma (25.7%) but none in high grade endometrioid carcinoma. Six from 19 patients (31.6%) who had <i>BRCA</i> mutation had no family history of breast and ovarian cancers. Higher frequency of <i>BRCA</i> mutation was detected in patients with fallopian tube cancer; 3 in 5 patients (60%) followed by peritoneal cancer; 2 in 4 patients (50%), and EOC; 14 in 77 patients (18.2%).</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The frequency of <i>BRCA</i> mutation in high grade serous carcinoma was 25.7%, none was found in high grade endometrioid carcinoma. High cost, unavailability of genetic testing, limited number of geneticists, may be barriers in limited resource countries. Selected patients especially high grade serous carcinoma should be considered initially.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Manchana</LastName>
                    <ForeName>Tarinee</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Phoolcharoen</LastName>
                    <ForeName>Natacha</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tantbirojn</LastName>
                    <ForeName>Patou</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Gynecologic Pathology and Cytology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Gynecol Oncol Rep</MedlineTA>
            <NlmUniqueID>101652231</NlmUniqueID>
            <ISSNLinking>2352-5789</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA mutation</Keyword>
            <Keyword MajorTopicYN="N">Epithelial ovarian cancer</Keyword>
            <Keyword MajorTopicYN="N">High grade endometrioid carcinoma</Keyword>
            <Keyword MajorTopicYN="N">High grade serous carcinoma</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31467961</ArticleId>
            <ArticleId IdType="doi">10.1016/j.gore.2019.07.007</ArticleId>
            <ArticleId IdType="pii">S2352-5789(19)30069-4</ArticleId>
            <ArticleId IdType="pmc">PMC6710551</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31461380</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-7755</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
                <ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic Variant.</ArticleTitle>
            <Pagination>
                <MedlinePgn>JCO1901304</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.19.01304</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Talazoparib has demonstrated efficacy in patients with <i>BRCA</i>-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline <i>BRCA</i> pathogenic variant (g<i>BRCA</i>-positive) and operable breast cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Eligibility included 1 cm or larger invasive tumor and g<i>BRCA</i>-positive disease. Human epidermal growth factor receptor 2-positive tumors were excluded. Twenty patients underwent a pretreatment biopsy, 6 months of once per day oral talazoparib (1 mg), followed by definitive surgery. Patients received adjuvant therapy at physician's discretion. The primary end point was residual cancer burden (RCB). With 20 patients, the RCB-0 plus RCB-I response rate can be estimated with a 95% CI with half width less than 20%.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty patients were enrolled from August 2016 to September 2017. Median age was 38 years (range, 23 to 58 years); 16 patients were g<i>BRCA</i>1 positive and 4 patients were g<i>BRCA</i>2 positive. Fifteen patients had triple-negative breast cancer (estrogen receptor/progesterone receptor &lt; 10%), and five had hormone receptor-positive disease. Five patients had clinical stage I disease, 12 had stage II, and three had stage III, including one patient with inflammatory breast carcinoma and one with metaplastic chondrosarcomatous carcinoma. One patient chose to receive chemotherapy before surgery and was not included in RCB analyses. RCB-0 (pathologic complete response) rate was 53% and RCB-0/I was 63%. Eight patients (40%) had grade 3 anemia and required a transfusion, three patients had grade 3 neutropenia, and 1 patient had grade 4 thrombocytopenia. Common grade 1 or 2 toxicities were nausea, fatigue, neutropenia, alopecia, dizziness, and dyspnea. Toxicities were managed by dose reduction and transfusions. Nine patients required dose reduction.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Neoadjuvant single-agent oral talazoparib once per day for 6 months without chemotherapy produced substantial RCB-0 rate with manageable toxicity. The substantive pathologic response to single-agent talazoparib supports the larger, ongoing neoadjuvant trial (ClinicalTrials.gov identifier: NCT03499353).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Litton</LastName>
                    <ForeName>Jennifer K</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scoggins</LastName>
                    <ForeName>Marion E</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hess</LastName>
                    <ForeName>Kenneth R</ForeName>
                    <Initials>KR</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adrada</LastName>
                    <ForeName>Beatriz E</ForeName>
                    <Initials>BE</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murthy</LastName>
                    <ForeName>Rashmi K</ForeName>
                    <Initials>RK</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Damodaran</LastName>
                    <ForeName>Senthil</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DeSnyder</LastName>
                    <ForeName>Sarah M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brewster</LastName>
                    <ForeName>Abenaa M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barcenas</LastName>
                    <ForeName>Carlos H</ForeName>
                    <Initials>CH</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valero</LastName>
                    <ForeName>Vicente</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Whitman</LastName>
                    <ForeName>Gary J</ForeName>
                    <Initials>GJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schwartz-Gomez</LastName>
                    <ForeName>Jill</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mittendorf</LastName>
                    <ForeName>Elizabeth A</ForeName>
                    <Initials>EA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Brigham and Women's Hospital, Boston, MA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Alastair M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Baylor College of Medicine, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Helgason</LastName>
                    <ForeName>Thorunn</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ibrahim</LastName>
                    <ForeName>Nuhad</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Piwnica-Worms</LastName>
                    <ForeName>Helen</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moulder</LastName>
                    <ForeName>Stacy L</ForeName>
                    <Initials>SL</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arun</LastName>
                    <ForeName>Banu K</ForeName>
                    <Initials>BK</Initials>
                    <AffiliationInfo>
                        <Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT03499353</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Clin Oncol</MedlineTA>
            <NlmUniqueID>8309333</NlmUniqueID>
            <ISSNLinking>0732-183X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31461380</ArticleId>
            <ArticleId IdType="doi">10.1200/JCO.19.01304</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">31456944</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2234-943X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in oncology</Title>
                <ISOAbbreviation>Front Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.</ArticleTitle>
            <Pagination>
                <MedlinePgn>759</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2019.00759</ELocationID>
            <Abstract>
                <AbstractText>Sensitivity to endocrine therapy of patients with estrogen receptor (ER)-positive metastatic breast cancer and germline <i>BRCA1/2</i> mutations is not yet fully elucidated. Furthermore, the registration trials of CDK 4/6 inhibitors in combination with endocrine therapy lacked of a pre-specified subgroup analysis in <i>BRCA1/2</i> mutation carriers. We report clinical history of two patients with BRCA-mutated, ER-positive metastatic breast cancer treated with letrozole plus the CDK 4/6 inhibitor palbociclib. Biological and clinical implications of the treatment outcome observed in the two cases are discussed with the knowledge of scientific evidence to date available. Overall, biological rationale, preclinical, and clinical data support the prominent role of CDK 4/6 inhibitors plus endocrine therapy, even in combination with PARP inhibitors, in the treatment of BRCA-mutated, ER-positive breast cancers. However, the interaction between Cyclin/CDK pathway, ER and BRCA is complex and evidences reported so far, albeit reliable, await confirmation in the context of future randomized clinical trials.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Militello</LastName>
                    <ForeName>Anna Maria</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Unit and Cancer Genetics Service, University Hospital of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zielli</LastName>
                    <ForeName>Teresa</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Unit and Cancer Genetics Service, University Hospital of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boggiani</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Unit and Cancer Genetics Service, University Hospital of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michiara</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Unit and Cancer Genetics Service, University Hospital of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naldi</LastName>
                    <ForeName>Nadia</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Unit and Cancer Genetics Service, University Hospital of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bortesi</LastName>
                    <ForeName>Beatrice</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Unit and Cancer Genetics Service, University Hospital of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zanelli</LastName>
                    <ForeName>Paola</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Genetics Unit, University Hospital of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uliana</LastName>
                    <ForeName>Vera</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Genetics Unit, University Hospital of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giuliotti</LastName>
                    <ForeName>Sara</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Radiology Unit, University Hospital of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Musolino</LastName>
                    <ForeName>Antonino</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Unit and Cancer Genetics Service, University Hospital of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Oncol</MedlineTA>
            <NlmUniqueID>101568867</NlmUniqueID>
            <ISSNLinking>2234-943X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA</Keyword>
            <Keyword MajorTopicYN="N">CDK4/6 inhibitor</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">cyclin D1</Keyword>
            <Keyword MajorTopicYN="N">endocrine therapy</Keyword>
            <Keyword MajorTopicYN="N">estrogen receptor</Keyword>
            <Keyword MajorTopicYN="N">homologous recombination</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31456944</ArticleId>
            <ArticleId IdType="doi">10.3389/fonc.2019.00759</ArticleId>
            <ArticleId IdType="pmc">PMC6700293</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">31449760</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>31</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-7658</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>28</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Expert opinion on investigational drugs</Title>
                <ISOAbbreviation>Expert Opin Investig Drugs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.</ArticleTitle>
            <Pagination>
                <MedlinePgn>771-785</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/13543784.2019.1657403</ELocationID>
            <Abstract>
                <AbstractText><b>Introduction</b>: Molecular analyzes including molecular descriptor/phenotype interactions have led to better characterization of epithelial ovarian cancer patients, including a definition of a BRCA wild-type (BRCAwt) phenotype. Understanding how and when to use agents targeted against dependent BRCAwt pathways or other molecular events at disease progression is an important translational and therapeutic direction in ovarian cancer research. <b>Areas covered</b>: In this overview, we provide definitions and descriptions of a BRCAwt genotype and phenotype. We discuss novel investigational drugs that hold promise for the treatment of BRCAwt ovarian cancer, including inhibitors of poly(ADP-ribose) polymerase, ribonucleotide reductase, DNA protein kinase-catalytic subunit, ataxia-telangiectasia-mutated kinase (ATM), ataxia-telangiectasia mutated and Rad3-related kinase (ATR), CHK 1/2, cyclin kinases, glutaminase-1, WEE1 kinase, as well as tumor microenvironment and angiogenesis inhibitors. This article explores the known and the emerging areas of clinical research on patients with BRCAwt ovarian cancer. <b>Expert opinion</b>: Discovery of molecular changes tied to annotated disease information, along with an expanding array of pathway targets and targeted therapeutic agents, creates optimism and opportunity for women with ovarian cancer. Using precision oncology approaches, clinical researchers are, and will be, poised to select more effective treatments for ovarian cancer patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ivy</LastName>
                    <ForeName>S Percy</ForeName>
                    <Initials>SP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Therapy Evaluation Program, National Cancer Institute (NCI) , Bethesda , MD , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kunos</LastName>
                    <ForeName>Charles A</ForeName>
                    <Initials>CA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Therapy Evaluation Program, National Cancer Institute (NCI) , Bethesda , MD , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arnaldez</LastName>
                    <ForeName>Fernanda I</ForeName>
                    <Initials>FI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Therapy Evaluation Program, National Cancer Institute (NCI) , Bethesda , MD , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kohn</LastName>
                    <ForeName>Elise C</ForeName>
                    <Initials>EC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Therapy Evaluation Program, National Cancer Institute (NCI) , Bethesda , MD , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Expert Opin Investig Drugs</MedlineTA>
            <NlmUniqueID>9434197</NlmUniqueID>
            <ISSNLinking>1354-3784</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ATM</Keyword>
            <Keyword MajorTopicYN="N">ATR</Keyword>
            <Keyword MajorTopicYN="N">BRCA wild type</Keyword>
            <Keyword MajorTopicYN="N">BRCAwt</Keyword>
            <Keyword MajorTopicYN="N">CHK1</Keyword>
            <Keyword MajorTopicYN="N">CHK2</Keyword>
            <Keyword MajorTopicYN="N">DNA damage repair</Keyword>
            <Keyword MajorTopicYN="N">DNA repair deficiencies</Keyword>
            <Keyword MajorTopicYN="N">DNA-PKcs</Keyword>
            <Keyword MajorTopicYN="N">Homologous recombination</Keyword>
            <Keyword MajorTopicYN="N">PARP</Keyword>
            <Keyword MajorTopicYN="N">biomarkers</Keyword>
            <Keyword MajorTopicYN="N">cell cycle</Keyword>
            <Keyword MajorTopicYN="N">high grade serous ovarian cancer</Keyword>
            <Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31449760</ArticleId>
            <ArticleId IdType="doi">10.1080/13543784.2019.1657403</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31446616</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4919</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular and cellular biochemistry</Title>
                <ISOAbbreviation>Mol. Cell. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>BRCA-1 depletion impairs pro-inflammatory polarization and activation of RAW 264.7 macrophages in a NF-κB-dependent mechanism.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11010-019-03605-9</ELocationID>
            <Abstract>
                <AbstractText>BRCA-1 is a nuclear protein involved in DNA repair, transcriptional regulation, and cell cycle control. Its involvement in other cellular processes has been described. Here, we aimed to investigate the role of BRCA-1 in macrophages M(LPS), M(IL-4), and tumor cell-induced differentiation. We used siRNAs to knockdown BRCA-1 in RAW 264.7 macrophages exposed to LPS, IL-4, and C6 glioma cells conditioned medium (CMC6), and evaluated macrophage differentiation markers and functional phagocytic activity as well as DNA damage and cell survival in the presence and absence of BRCA-1. LPS and CMC6, but not by IL-4, increased DNA damage in macrophages, and this effect was more pronounced in BRCA-1-depleted cells, including M(IL-4). BRCA-1 depletion impaired expression of pro-inflammatory cytokines, TNF-α and IL-6, and reduced the phagocytic activity of macrophages in response to LPS. In CMC6-induced differentiation, BRCA-1 knockdown inhibited TNF-α and IL-6 expression which was accompanied by upregulation of the anti-inflammatory markers IL-10 and TGF-β and reduced phagocytosis. In contrast, M(IL-4) phenotype was not affected by BRCA-1 status. Molecular docking predicted that the conserved BRCA-1 domain BRCT can interact with the p65 subunit of NF-κB. Immunofluorescence assays showed that BRCA-1 and p65 co-localize in the nucleus of LPS-treated macrophages and reporter gene assay showed that depletion of BRCA-1 decreased LPS and CMC6-induced NF-κB transactivation. IL-4 had no effect upon NF-κB. Taken together, our findings suggest a role of BRCA-1 in macrophage differentiation and phagocytosis induced by LPS and tumor cells secretoma, but not IL-4, in a mechanism associated with inhibition of NF-κB.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Morrone</LastName>
                    <ForeName>Maurilio da Silva</ForeName>
                    <Initials>MDS</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8144-0347</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquímica, Centro de Estudos de Estresse Oxidativo, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 - Anexo Depto. Bioquímica, Lab 32, Porto Alegre, RS, CEP 90035-003, Brazil. maurilio.bio@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Somensi</LastName>
                    <ForeName>Nauana</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquímica, Centro de Estudos de Estresse Oxidativo, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 - Anexo Depto. Bioquímica, Lab 32, Porto Alegre, RS, CEP 90035-003, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Franz</LastName>
                    <ForeName>Lucas</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquímica, Centro de Estudos de Estresse Oxidativo, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 - Anexo Depto. Bioquímica, Lab 32, Porto Alegre, RS, CEP 90035-003, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramos</LastName>
                    <ForeName>Vitor de Miranda</ForeName>
                    <Initials>VM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquímica, Centro de Estudos de Estresse Oxidativo, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 - Anexo Depto. Bioquímica, Lab 32, Porto Alegre, RS, CEP 90035-003, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gasparotto</LastName>
                    <ForeName>Juciano</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquímica, Centro de Estudos de Estresse Oxidativo, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 - Anexo Depto. Bioquímica, Lab 32, Porto Alegre, RS, CEP 90035-003, Brazil.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Laboratorio de Toxicología Ambiental, Departamento de Ingeniería Civil y Ambiental, Universidad de la Costa, Calle 58 #55-66, 080002, Barranquilla, Atlántico, Colombia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>da Rosa</LastName>
                    <ForeName>Helen Taís</ForeName>
                    <Initials>HT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquímica, Centro de Estudos de Estresse Oxidativo, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 - Anexo Depto. Bioquímica, Lab 32, Porto Alegre, RS, CEP 90035-003, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sartori</LastName>
                    <ForeName>Marcelo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquímica, Centro de Estudos de Estresse Oxidativo, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 - Anexo Depto. Bioquímica, Lab 32, Porto Alegre, RS, CEP 90035-003, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Figueiró</LastName>
                    <ForeName>Fabrício</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquímica, Centro de Estudos de Estresse Oxidativo, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 - Anexo Depto. Bioquímica, Lab 32, Porto Alegre, RS, CEP 90035-003, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gelain</LastName>
                    <ForeName>Daniel Pens</ForeName>
                    <Initials>DP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquímica, Centro de Estudos de Estresse Oxidativo, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 - Anexo Depto. Bioquímica, Lab 32, Porto Alegre, RS, CEP 90035-003, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zanotto-Filho</LastName>
                    <ForeName>Alfeu</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratório de Farmacologia e Bioquímica do Câncer, Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moreira</LastName>
                    <ForeName>José Cláudio Fonseca</ForeName>
                    <Initials>JCF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquímica, Centro de Estudos de Estresse Oxidativo, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 - Anexo Depto. Bioquímica, Lab 32, Porto Alegre, RS, CEP 90035-003, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>17/2551-001408-1</GrantID>
                    <Agency>Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>16/2551-0000499-4</GrantID>
                    <Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Mol Cell Biochem</MedlineTA>
            <NlmUniqueID>0364456</NlmUniqueID>
            <ISSNLinking>0300-8177</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA-1</Keyword>
            <Keyword MajorTopicYN="N">Inflammation</Keyword>
            <Keyword MajorTopicYN="N">M(LPS) and M(IL-4) polarization</Keyword>
            <Keyword MajorTopicYN="N">Macrophage activation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31446616</ArticleId>
            <ArticleId IdType="doi">10.1007/s11010-019-03605-9</ArticleId>
            <ArticleId IdType="pii">10.1007/s11010-019-03605-9</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31446213</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0852</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>120</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of cancer (Oxford, England : 1990)</Title>
                <ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>20-30</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0959-8049(19)30415-0</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2019.06.023</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The phase III OlympiAD study (NCT02000622) showed a statistically significant progression-free survival benefit with olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA mutation and human epidermal growth factor receptor 2-negative metastatic breast cancer. From this study, we report the effect of olaparib on health-related quality of life (HRQoL).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients were randomised 2:1 to olaparib monotherapy (300 mg twice daily) or single-agent TPC. The primary HRQoL end-point was mean change from baseline in the two-item global health status/QoL score determined from patient-completed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module (EORTC QLQ-C30) questionnaires and assessed using a mixed model for repeated measures. Symptoms and functioning domains, best overall response and time to deterioration of QoL were also evaluated.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall questionnaire compliance rates were 93.2% for olaparib and 76.3% for TPC. Between-treatment global health status/QoL comparison showed a significant improvement in the olaparib arm versus the TPC arm, with mean change of 3.9 (standard deviation 1.2) versus -3.6 (2.2), a difference of 7.5 points (95% confidence interval [CI]: 2.48, 12.44; P = 0.0035). A higher proportion of patients in the olaparib arm showed a best overall response of 'improvement' in global health status/QoL (33.7% vs 13.4%). Median time to global health status/QoL deterioration was not reached in olaparib patients and was 15.3 months for TPC patients (hazard ratio: 0.44 [95% CI: 0.25, 0.77]; P = 0.004). For EORTC QLQ-C30 symptoms and functioning subscales, only nausea/vomiting symptom score was worse in the olaparib arm than in the TPC arm (across all visits compared with baseline).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">HRQoL was consistently improved for patients treated with olaparib, compared with chemotherapy TPC.</AbstractText>
                <CopyrightInformation>Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Robson</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: robsonm@mskcc.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruddy</LastName>
                    <ForeName>Kathryn J</ForeName>
                    <Initials>KJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Im</LastName>
                    <ForeName>Seock-Ah</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Senkus</LastName>
                    <ForeName>Elżbieta</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical University of Gdańsk, Gdańsk, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Binghe</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Domchek</LastName>
                    <ForeName>Susan M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Basser Center, University of Pennsylvania, Philadelphia, PA, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masuda</LastName>
                    <ForeName>Norikazu</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Hospital Organization, Osaka National Hospital, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Hospital of Jilin University, Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tung</LastName>
                    <ForeName>Nadine</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Beth Israel Deaconess Medical Center, Dana-Farber Harvard Cancer Center, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Armstrong</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Delaloge</LastName>
                    <ForeName>Suzette</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Gustave Roussy, Villejuif, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bannister</LastName>
                    <ForeName>Wendy</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>AstraZeneca, Milton, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goessl</LastName>
                    <ForeName>Carsten</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>AstraZeneca, Gaithersburg, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Degboe</LastName>
                    <ForeName>Arnold</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>AstraZeneca, Gaithersburg, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hettle</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>AstraZeneca, Milton, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Conte</LastName>
                    <ForeName>Pierfranco</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS, Padova, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Cancer</MedlineTA>
            <NlmUniqueID>9005373</NlmUniqueID>
            <ISSNLinking>0959-8049</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">BRCA</Keyword>
            <Keyword MajorTopicYN="Y">Breast cancer</Keyword>
            <Keyword MajorTopicYN="Y">EORTC QLQ-C30</Keyword>
            <Keyword MajorTopicYN="Y">Health-related quality of life</Keyword>
            <Keyword MajorTopicYN="Y">Olaparib</Keyword>
            <Keyword MajorTopicYN="Y">OlympiAD</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31446213</ArticleId>
            <ArticleId IdType="pii">S0959-8049(19)30415-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejca.2019.06.023</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31429903</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1538-3598</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>322</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>08</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA</Title>
                <ISOAbbreviation>JAMA</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.</ArticleTitle>
            <Pagination>
                <MedlinePgn>652-665</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2019.10987</ELocationID>
            <Abstract>
                <AbstractText Label="Importance">Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is the most common cancer after nonmelanoma skin cancer and the second leading cause of cancer death. In the general population, BRCA1/2 mutations occur in an estimated 1 in 300 to 500 women and account for 5% to 10% of breast cancer cases and 15% of ovarian cancer cases.</AbstractText>
                <AbstractText Label="Objective">To update the 2013 US Preventive Services Task Force (USPSTF) recommendation on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer.</AbstractText>
                <AbstractText Label="Evidence Review">The USPSTF reviewed the evidence on risk assessment, genetic counseling, and genetic testing for potentially harmful BRCA1/2 mutations in asymptomatic women who have never been diagnosed with BRCA-related cancer, as well as those with a previous diagnosis of breast, ovarian, tubal, or peritoneal cancer who have completed treatment and are considered cancer free. In addition, the USPSTF reviewed interventions to reduce the risk for breast, ovarian, tubal, or peritoneal cancer in women with potentially harmful BRCA1/2 mutations, including intensive cancer screening, medications, and risk-reducing surgery.</AbstractText>
                <AbstractText Label="Findings">For women whose family or personal history is associated with an increased risk for harmful mutations in the BRCA1/2 genes, or who have an ancestry associated with BRCA1/2 gene mutations, there is adequate evidence that the benefits of risk assessment, genetic counseling, genetic testing, and interventions are moderate. For women whose personal or family history or ancestry is not associated with an increased risk for harmful mutations in the BRCA1/2 genes, there is adequate evidence that the benefits of risk assessment, genetic counseling, genetic testing, and interventions are small to none. Regardless of family or personal history, the USPSTF found adequate evidence that the overall harms of risk assessment, genetic counseling, genetic testing, and interventions are small to moderate.</AbstractText>
                <AbstractText Label="Conclusions and Recommendation">The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with BRCA1/2 gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing. (B recommendation) The USPSTF recommends against routine risk assessment, genetic counseling, or genetic testing for women whose personal or family history or ancestry is not associated with potentially harmful BRCA1/2 gene mutations. (D recommendation).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <CollectiveName>US Preventive Services Task Force</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Owens</LastName>
                    <ForeName>Douglas K</ForeName>
                    <Initials>DK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Veterans Affairs Palo Alto Health Care System, Palo Alto, California.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Stanford University, Stanford, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davidson</LastName>
                    <ForeName>Karina W</ForeName>
                    <Initials>KW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krist</LastName>
                    <ForeName>Alex H</ForeName>
                    <Initials>AH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fairfax Family Practice Residency, Fairfax, Virginia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Virginia Commonwealth University, Richmond.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barry</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cabana</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California, San Francisco.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caughey</LastName>
                    <ForeName>Aaron B</ForeName>
                    <Initials>AB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oregon Health &amp; Science University, Portland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doubeni</LastName>
                    <ForeName>Chyke A</ForeName>
                    <Initials>CA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mayo Clinic, Rochester, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Epling</LastName>
                    <ForeName>John W</ForeName>
                    <Initials>JW</Initials>
                    <Suffix>Jr</Suffix>
                    <AffiliationInfo>
                        <Affiliation>Virginia Tech Carilion School of Medicine, Roanoke.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kubik</LastName>
                    <ForeName>Martha</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Temple University, Philadelphia, Pennsylvania.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Landefeld</LastName>
                    <ForeName>C Seth</ForeName>
                    <Initials>CS</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Alabama at Birmingham.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mangione</LastName>
                    <ForeName>Carol M</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California, Los Angeles.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pbert</LastName>
                    <ForeName>Lori</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Massachusetts Medical School, Worcester.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silverstein</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Boston University, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simon</LastName>
                    <ForeName>Melissa A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Northwestern University, Evanston, Illinois.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tseng</LastName>
                    <ForeName>Chien-Wen</ForeName>
                    <Initials>CW</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Hawaii, Honolulu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Pacific Health Research and Education Institute, Honolulu, Hawaii.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>John B</ForeName>
                    <Initials>JB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA</MedlineTA>
            <NlmUniqueID>7501160</NlmUniqueID>
            <ISSNLinking>0098-7484</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>JAMA. 2019 Aug 20;322(7):619-621</RefSource>
                <PMID Version="1">31429878</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="SummaryForPatientsIn">
                <RefSource>JAMA. 2019 Aug 20;322(7):702</RefSource>
                <PMID Version="1">31429898</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005185" MajorTopicYN="N">Fallopian Tube Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019398" MajorTopicYN="Y">Genes, BRCA1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024522" MajorTopicYN="Y">Genes, BRCA2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005817" MajorTopicYN="Y">Genetic Counseling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005820" MajorTopicYN="Y">Genetic Testing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010534" MajorTopicYN="N">Peritoneal Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31429903</ArticleId>
            <ArticleId IdType="pii">2748515</ArticleId>
            <ArticleId IdType="doi">10.1001/jama.2019.10987</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31429902</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1538-3598</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>322</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>08</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA</Title>
                <ISOAbbreviation>JAMA</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</ArticleTitle>
            <Pagination>
                <MedlinePgn>666-685</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2019.8430</ELocationID>
            <Abstract>
                <AbstractText Label="Importance">Pathogenic mutations in breast cancer susceptibility genes BRCA1 and BRCA2 increase risks for breast, ovarian, fallopian tube, and peritoneal cancer in women; interventions reduce risk in mutation carriers.</AbstractText>
                <AbstractText Label="Objective">To update the 2013 US Preventive Services Task Force review on benefits and harms of risk assessment, genetic counseling, and genetic testing for BRCA1/2-related cancer in women.</AbstractText>
                <AbstractText Label="Data Sources">Cochrane libraries; MEDLINE, PsycINFO, EMBASE (January 1, 2013, to March 6, 2019, for updates; January 1, 1994, to March 6, 2019, for new key questions and populations); reference lists.</AbstractText>
                <AbstractText Label="Study Selection">Discriminatory accuracy studies, randomized clinical trials (RCTs), and observational studies of women without recently diagnosed BRCA1/2-related cancer.</AbstractText>
                <AbstractText Label="Data Extraction and Synthesis">Data on study methods, setting, population characteristics, eligibility criteria, interventions, numbers enrolled and lost to follow-up, outcome ascertainment, and results were abstracted. Two reviewers independently assessed study quality.</AbstractText>
                <AbstractText Label="Main Outcomes and Measures">Cancer incidence and mortality; discriminatory accuracy of risk assessment tools for BRCA1/2 mutations; benefits and harms of risk assessment, genetic counseling, genetic testing, and risk-reducing interventions.</AbstractText>
                <AbstractText Label="Results">For this review, 103 studies (110 articles; N = 92 712) were included. No studies evaluated the effectiveness of risk assessment, genetic counseling, and genetic testing in reducing incidence and mortality of BRCA1/2-related cancer. Fourteen studies (n = 43 813) of 8 risk assessment tools to guide referrals to genetic counseling demonstrated moderate to high accuracy (area under the receiver operating characteristic curve, 0.68-0.96). Twenty-eight studies (n = 8060) indicated that genetic counseling was associated with reduced breast cancer worry, anxiety, and depression; increased understanding of risk; and decreased intention for testing. Twenty studies (n = 4322) showed that breast cancer worry and anxiety were higher after testing for women with positive results and lower for others; understanding of risk was higher after testing. In 8 RCTs (n = 54 651), tamoxifen (relative risk [RR], 0.69 [95% CI, 0.59-0.84]; 4 trials), raloxifene (RR, 0.44 [95% CI, 0.24-0.80]; 2 trials), and aromatase inhibitors (RR, 0.45 [95% CI, 0.26-0.70]; 2 trials) were associated with lower risks of invasive breast cancer compared with placebo; results were not specific to mutation carriers. Mastectomy was associated with 90% to 100% reduction in breast cancer incidence (6 studies; n = 2546) and 81% to 100% reduction in breast cancer mortality (1 study; n = 639); oophorectomy was associated with 69% to 100% reduction in ovarian cancer (2 studies; n = 2108); complications were common with mastectomy.</AbstractText>
                <AbstractText Label="Conclusions and Relevance">Among women without recently diagnosed BRCA1/2-related cancer, the benefits and harms of risk assessment, genetic counseling, and genetic testing to reduce cancer incidence and mortality have not been directly evaluated by current research.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>Heidi D</ForeName>
                    <Initials>HD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pacific Northwest Evidence-based Practice Center, Oregon Health &amp; Science University, Portland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pappas</LastName>
                    <ForeName>Miranda</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pacific Northwest Evidence-based Practice Center, Oregon Health &amp; Science University, Portland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cantor</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pacific Northwest Evidence-based Practice Center, Oregon Health &amp; Science University, Portland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haney</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pacific Northwest Evidence-based Practice Center, Oregon Health &amp; Science University, Portland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holmes</LastName>
                    <ForeName>Rebecca</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pacific Northwest Evidence-based Practice Center, Oregon Health &amp; Science University, Portland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
                <PublicationType UI="D000078182">Systematic Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA</MedlineTA>
            <NlmUniqueID>7501160</NlmUniqueID>
            <ISSNLinking>0098-7484</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>JAMA. 2019 Aug 20;322(7):619-621</RefSource>
                <PMID Version="1">31429878</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005185" MajorTopicYN="N">Fallopian Tube Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019398" MajorTopicYN="Y">Genes, BRCA1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024522" MajorTopicYN="Y">Genes, BRCA2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005817" MajorTopicYN="Y">Genetic Counseling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005820" MajorTopicYN="Y">Genetic Testing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010534" MajorTopicYN="N">Peritoneal Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31429902</ArticleId>
            <ArticleId IdType="pii">2748514</ArticleId>
            <ArticleId IdType="doi">10.1001/jama.2019.8430</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31429898</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1538-3598</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>322</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>08</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA</Title>
                <ISOAbbreviation>JAMA</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Should I Be Tested for BRCA Mutations?</ArticleTitle>
            <Pagination>
                <MedlinePgn>702</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2019.11251</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Jill</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D029282">Patient Education Handout</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA</MedlineTA>
            <NlmUniqueID>7501160</NlmUniqueID>
            <ISSNLinking>0098-7484</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="OriginalReportIn">
                <RefSource>JAMA. 2019 Aug 20;322(7):652-665</RefSource>
                <PMID Version="1">31429903</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005185" MajorTopicYN="N">Fallopian Tube Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019398" MajorTopicYN="Y">Genes, BRCA1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024522" MajorTopicYN="Y">Genes, BRCA2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005817" MajorTopicYN="N">Genetic Counseling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005820" MajorTopicYN="Y">Genetic Testing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010534" MajorTopicYN="N">Peritoneal Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31429898</ArticleId>
            <ArticleId IdType="pii">2748510</ArticleId>
            <ArticleId IdType="doi">10.1001/jama.2019.11251</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31429868</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2168-6262</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA surgery</Title>
                <ISOAbbreviation>JAMA Surg</ISOAbbreviation>
            </Journal>
            <ArticleTitle>US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamasurg.2019.3184</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Newman</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Interdisciplinary Breast Program, NewYork-Presbyterian/Weill Cornell Medical Center, New York.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>International Center for the Study of Breast Cancer Subtypes, NewYork-Presbyterian/Weill Cornell Medical Center, New York.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Breast Surgery, Department of Surgery, NewYork-Presbyterian/Weill Cornell Medical Center, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA Surg</MedlineTA>
            <NlmUniqueID>101589553</NlmUniqueID>
            <ISSNLinking>2168-6254</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31429868</ArticleId>
            <ArticleId IdType="pii">2748637</ArticleId>
            <ArticleId IdType="doi">10.1001/jamasurg.2019.3184</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31426925</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4733</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</Title>
                <ISOAbbreviation>Value Health</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.</ArticleTitle>
            <Pagination>
                <MedlinePgn>854-862</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1098-3015(19)30177-9</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jval.2019.03.008</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To develop a validated model for evaluating the real-world effectiveness of long-term clinical management strategies for women with germline BRCA1 or BRCA2 pathogenic variants.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A microsimulation model was developed that included a BRCA-specific natural history for breast and ovarian cancer, a clinical framework for carrier follow-up, and cancer risk management strategies (breast screening, risk-reducing mastectomy, and bilateral salpingo-oophorectomy). Adherence rates and outcomes for breast screening and risk-reducing surgery were obtained from BRCA carriers seen through a familial cancer service in Melbourne, Australia. The model was assessed for internal and external validity. The model was used to compare women perfectly adhering to screening recommendations versus actual adherence of the clinical cohort.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The model accurately predicted cancer incidence, pathology, and mortality. Using actual adherence for breast screening resulted in additional breast cancer deaths (per 1000 women: BRCA1, 2.7; BRCA2, 1.6) compared with perfect screening adherence. This decreased average life expectancy by 0.30 life-years for BRCA1 and 0.07 life-years for BRCA2. When carriers had access to risk-reducing mastectomy, the benefit from improved screening adherence was not significant.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The developed model is a good descriptor of BRCA carriers' lifetime trajectory and its modification by use of risk management strategies alone or in combination. Evaluations of breast screening in BRCA carriers may overestimate the benefits of screening programs unless adherence is considered. By incorporating real-world clinical practice and patient behavior, this model can assist in developing clinical services and improving clinical outcomes for carriers.</AbstractText>
                <CopyrightInformation>Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Petelin</LastName>
                    <ForeName>Lara</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: lara.petelin@petermac.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hossack</LastName>
                    <ForeName>Lucinda</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Genetics, Austin Health, Austin Hospital, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mitchell</LastName>
                    <ForeName>Gillian</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liew</LastName>
                    <ForeName>Danny</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trainer</LastName>
                    <ForeName>Alison H</ForeName>
                    <Initials>AH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Royal Melbourne Hospital, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>James</LastName>
                    <ForeName>Paul A</ForeName>
                    <Initials>PA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Royal Melbourne Hospital, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Value Health</MedlineTA>
            <NlmUniqueID>100883818</NlmUniqueID>
            <ISSNLinking>1098-3015</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA</Keyword>
            <Keyword MajorTopicYN="N">prevention</Keyword>
            <Keyword MajorTopicYN="N">screening</Keyword>
            <Keyword MajorTopicYN="N">simulation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31426925</ArticleId>
            <ArticleId IdType="pii">S1098-3015(19)30177-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jval.2019.03.008</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31421928</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-3088</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>29</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Trends in cell biology</Title>
                <ISOAbbreviation>Trends Cell Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>820-834</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0962-8924(19)30124-2</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tcb.2019.07.008</ELocationID>
            <Abstract>
                <AbstractText>Poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with deficiency for homologous recombination (HR), a pathway essential for DNA double-strand break repair. PARP inhibitors (PARPi) therefore hold great promise for the treatment of tumors with disruptive mutations in BRCA1/2 or other HR factors. Unfortunately, PARPi resistance has proved to be a major problem in the clinic. Knowledge about PARPi resistance is expanding quickly, revealing four main mechanisms that alter drug availability, affect (de)PARylation enzymes, restore HR, or restore replication fork stability. We discuss how studies on resistance mechanisms have yielded important insights into the regulation of DNA double-strand break (DSB) repair and replication fork protection, and how these studies could pave the way for novel treatment options to target resistance mechanisms or acquired vulnerabilities.</AbstractText>
                <CopyrightInformation>Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Noordermeer</LastName>
                    <ForeName>Sylvie M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Leiden University Medical Center, Department of Human Genetics, Einthovenweg 20, 2333 ZC Leiden, The Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, The Netherlands. Electronic address: s.m.noordermeer@lumc.nl.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Attikum</LastName>
                    <ForeName>Haico</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Leiden University Medical Center, Department of Human Genetics, Einthovenweg 20, 2333 ZC Leiden, The Netherlands. Electronic address: h.van.attikum@lumc.nl.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Trends Cell Biol</MedlineTA>
            <NlmUniqueID>9200566</NlmUniqueID>
            <ISSNLinking>0962-8924</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA1/2</Keyword>
            <Keyword MajorTopicYN="N">DNA double-strand break repair</Keyword>
            <Keyword MajorTopicYN="N">PARP inhibitor resistance</Keyword>
            <Keyword MajorTopicYN="N">Shieldin</Keyword>
            <Keyword MajorTopicYN="N">cancer</Keyword>
            <Keyword MajorTopicYN="N">homologous recombination</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31421928</ArticleId>
            <ArticleId IdType="pii">S0962-8924(19)30124-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.tcb.2019.07.008</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31411802</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1447-0756</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The journal of obstetrics and gynaecology research</Title>
                <ISOAbbreviation>J. Obstet. Gynaecol. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jog.14090</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">Subjects with germline BRCA1/2 mutations (gBRCAm) have an increased risk of developing breast cancer and ovarian cancer. At present, knowledge of BRCA1/2 mutation frequency in Chinese patients with ovarian cancer is still insufficient, and the detailed clinical information of these patients is poorly understood.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 547 unselected ovarian cancer patients were enrolled, and their gBRCAm status was detected. Clinical characteristics including age, personal and family history, histopathologic diagnosis, carbohydrate antigen 125 (CA-125) level, ascites, Federation International of Gynecology and Obstetrics (FIGO) stage, residual lesions, platinum sensitivity, recurrence interval and survival information were collected. Accurate assessments of disease response were based on the RECIST standard or CA-125 level.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In 547 patients with ovarian cancer, we detected 129 (23.6%) patients with pathogenic mutations, 84 patients with BRCA1 mutations (15.4%) and 45 patients with BRCA2 mutations (8.2%). Twenty-five novel mutations were identified, and the mutation of BRCA1, c.5470_5477del8, was the most common mutation in this study. BRCA1/2 mutations were significantly associated with age; personal and family history; FIGO stage; secondary recurrence interval; sensitivity to platinum in 1st, 2nd and 3rd line treatment; and response to doxorubicin liposomes. Patients with BRCA1/2 mutations showed significant advantages in 3- and 5-year survival rates but no advantage in long-term survival.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">BRCA1/2 mutation prevalence in Chinese ovarian cancer patients is higher than the international rate. We recommend BRCA1/2 testing for patients with family histories and personal histories of malignancy and genetic counseling for cancer in healthy people with high-risk family histories.</AbstractText>
                <CopyrightInformation>© 2019 Japan Society of Obstetrics and Gynecology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bu</LastName>
                    <ForeName>Hualei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jingying</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Qingshui</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gynecologic Oncology Ward 1, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hou</LastName>
                    <ForeName>Jianqing</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology, Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Yuan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Xiaohang</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Yana</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Hongsheng</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Technical Department, Shanghai Topgen Biopharm Technology Co, Ltd, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Youzhong</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Beihua</ForeName>
                    <Initials>B</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0001-8300-4194</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>2015BAI13B05</GrantID>
                    <Agency>National Clinical Research Center for Gynecological Oncology</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>2016YFC1302601</GrantID>
                    <Agency>National Key Research and Development Program of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81572554</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Australia</Country>
            <MedlineTA>J Obstet Gynaecol Res</MedlineTA>
            <NlmUniqueID>9612761</NlmUniqueID>
            <ISSNLinking>1341-8076</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA</Keyword>
            <Keyword MajorTopicYN="N">Chinese ovarian cancer patient</Keyword>
            <Keyword MajorTopicYN="N">FIGO stage</Keyword>
            <Keyword MajorTopicYN="N">platinum sensitivity</Keyword>
            <Keyword MajorTopicYN="N">survival</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31411802</ArticleId>
            <ArticleId IdType="doi">10.1111/jog.14090</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31399819</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1534-4681</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                        <Day>09</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of surgical oncology</Title>
                <ISOAbbreviation>Ann. Surg. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1245/s10434-019-07704-1</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is limited data evaluating mastectomy skin flap complications of nipple-sparing mastectomy (NSM) in patients with BRCA gene mutations. The purpose of this study was to identify factors associated with post-operative complications in BRCA mutation carriers undergoing NSM.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Following institutional review board approval, we interrogated a prospectively collected institutional database for patients undergoing NSM who tested positive for BRCA1/2 mutations. Patient characteristics, preoperative details, and complications were evaluated. Digital mammogram was used to estimate the breast volume.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">From August 2009 to December 2017, 59 patients (2 males) with BRCA1/2 mutations underwent 114 NSMs. Ninety-two (80%) were risk-reduction surgeries. Thirty-two (28%) underwent single-stage reconstruction (24 autologous). The overall complication rate was 26.3% (N = 30), and 10.5% (N = 12) underwent unanticipated reoperation. 8.8% (N = 10) had full-thickness skin flap necrosis, 10.5% (N = 12) nipple necrosis, and 4.4% (N = 5) full-thickness nipple necrosis. These complications were associated with larger breast volume (799.4 cc vs. 544.1 cc, p &lt; 0.001) and greater body mass index (27.8 vs. 24.3, p &lt; 0.001). By univariate analysis, body mass index and breast volume greater than 675 cc were associated with significantly higher complication rate (odds ratios 1.2 and 4.5 respectively, p = 0.001).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study confirms that NSM in BRCA1/2 mutation carriers is associated with complications in one in four patients. Utilizing the preoperative mammograms to estimate breast size may be more helpful than breast cup size in counseling preoperatively the risks of complications.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Ko Un</ForeName>
                    <Initials>KU</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1495-9920</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA. koun.park@osumc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weiss</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosso</LastName>
                    <ForeName>Kelly</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, Banner MD Anderson, Gilbert, AZ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yi</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hunt</LastName>
                    <ForeName>Kelly</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuerer</LastName>
                    <ForeName>Henry</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hanson</LastName>
                    <ForeName>Summer E</ForeName>
                    <Initials>SE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Candelaria</LastName>
                    <ForeName>Rosalind</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tevis</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Division of Surgical Oncology, University of Colorado, Denver, CO, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Alastair</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Division of Surgical Oncology, Baylor College of Medicine, Houston, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Surg Oncol</MedlineTA>
            <NlmUniqueID>9420840</NlmUniqueID>
            <ISSNLinking>1068-9265</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31399819</ArticleId>
            <ArticleId IdType="doi">10.1245/s10434-019-07704-1</ArticleId>
            <ArticleId IdType="pii">10.1245/s10434-019-07704-1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31390031</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2574-3805</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA network open</Title>
                <ISOAbbreviation>JAMA Netw Open</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e198420</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2019.8420</ELocationID>
            <Abstract>
                <AbstractText Label="Importance" NlmCategory="UNASSIGNED">Preventive surgery is strongly recommended for individuals with a BRCA mutation at a young age to prevent ovarian cancer and improve overall survival. The overall effect of early surgical menopause on various health outcomes, including bone health, has not been clearly elucidated.</AbstractText>
                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">To evaluate the association of prophylactic bilateral salpingo-oophorectomy with bone mineral density (BMD) loss among individuals with a BRCA mutation.</AbstractText>
                <AbstractText Label="Design, Setting, and Participants" NlmCategory="UNASSIGNED">This retrospective cohort study of participants with a BRCA mutation who underwent oophorectomy through the University Health Network, Toronto, Ontario, Canada, recruited participants from January 2000 to May 2013. Eligibility criteria included having a BRCA mutation, at least 1 ovary intact prior to surgery, and no history of any cancer other than breast cancer. Bone mineral density was measured using dual-energy x-ray absorptiometry before and after surgery. Data analysis began in December 2018 and finished in January 2019.</AbstractText>
                <AbstractText Label="Main Outcomes and Measures" NlmCategory="UNASSIGNED">The annual change in BMD from baseline to follow-up was calculated for the following 3 anatomical locations: (1) lumbar spine, (2) femoral neck, and (3) total hip.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 95 women had both a baseline and postsurgery BMD measurement with a mean (SD) follow-up period of 22.0 (12.7) months. The mean (SD) age at oophorectomy was 48.0 (7.4) years. Among women who were premenopausal at time of surgery (50 [53%]), there was a decrease in BMD from baseline to follow-up across the lumbar spine (annual change, -3.45%; 95% CI, -4.61% to -2.29%), femoral neck (annual change, -2.85%; 95% CI, -3.79% to -1.91%), and total hip (annual change, -2.24%; 95% CI, -3.11% to -1.38%). Self-reported hormone therapy use was associated with significantly less bone loss at the lumbar spine (-2.00% vs -4.69%; P = .02) and total hip (-1.38% vs -3.21; P = .04) compared with no hormone therapy use. Among postmenopausal women at time of surgery (45 [47%]), there was also a significant decrease in BMD across the lumbar spine (annual change, -0.82%; 95% CI, -1.42% to -0.23%) and femoral neck (annual change, -0.68%; 95% CI, -1.33% to -0.04%) but not total hip (annual change, -0.18%; 95% CI, -0.82% to 0.46%).</AbstractText>
                <AbstractText Label="Conclusions and Relevance" NlmCategory="UNASSIGNED">This study found that oophorectomy was associated with postoperative bone loss, especially among women who were premenopausal at the time of surgery. Targeted management strategies should include routine BMD assessment and hormone therapy use to improve management of bone health in this population.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kotsopoulos</LastName>
                    <ForeName>Joanne</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Women's College Research Institute, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hall</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Women's College Research Institute, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Finch</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Women's College Research Institute, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Hanxian</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Osteoporosis Program, University Health Network, Centre of Excellence in Skeletal Health Assessment, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murphy</LastName>
                    <ForeName>Joan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosen</LastName>
                    <ForeName>Barry</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Osteoporosis Program, University Health Network, Centre of Excellence in Skeletal Health Assessment, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Narod</LastName>
                    <ForeName>Steven A</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Women's College Research Institute, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheung</LastName>
                    <ForeName>Angela M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Osteoporosis Program, University Health Network, Centre of Excellence in Skeletal Health Assessment, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA Netw Open</MedlineTA>
            <NlmUniqueID>101729235</NlmUniqueID>
            <ISSNLinking>2574-3805</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31390031</ArticleId>
            <ArticleId IdType="pii">2747474</ArticleId>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2019.8420</ArticleId>
            <ArticleId IdType="pmc">PMC6686775</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31385845</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1473-5709</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>28</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)</Title>
                <ISOAbbreviation>Eur. J. Cancer Prev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>BRCA test: what is the correct timing for surgery?</ArticleTitle>
            <Pagination>
                <MedlinePgn>460-462</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/CEJ.0000000000000509</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mirandola</LastName>
                    <ForeName>Sara</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>UOC Breast Unit, University of Verona, Major Civil Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Invento</LastName>
                    <ForeName>Alessandra</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>UOC Breast Unit, University of Verona, Major Civil Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Surci</LastName>
                    <ForeName>Niccolò</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pancreas and General Surgery, University of Verona, G.B. Rossi Hospital Verona, Verona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pollini</LastName>
                    <ForeName>Giovanni P</ForeName>
                    <Initials>GP</Initials>
                    <AffiliationInfo>
                        <Affiliation>UOC Breast Unit, University of Verona, Major Civil Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pellini</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>UOC Breast Unit, University of Verona, Major Civil Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Cancer Prev</MedlineTA>
            <NlmUniqueID>9300837</NlmUniqueID>
            <ISSNLinking>0959-8278</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31385845</ArticleId>
            <ArticleId IdType="doi">10.1097/CEJ.0000000000000509</ArticleId>
            <ArticleId IdType="pii">00008469-201909000-00015</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">31372057</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1179-1349</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical epidemiology</Title>
                <ISOAbbreviation>Clin Epidemiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A systematic review of the international prevalence of <i>BRCA</i> mutation in breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>543-561</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/CLEP.S206949</ELocationID>
            <Abstract>
                <AbstractText>A systematic review was conducted, summarizing international <i>BRCA 1</i> or <i>2</i> (<i>BRCA1/2</i>) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N&gt;100) studies, <i>BRCA1/2</i> mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1-9% on immunohistochemistry/human epidermal growth factor receptor 2-negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline <i>BRCA</i> (g<i>BRCA</i>) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, g<i>BRCA</i> mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). g<i>BRCA</i> mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, g<i>BRCA</i> mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unselected populations. Poor reporting of g<i>BRCA</i> status and basis of selection implies a need for further large well-reported <i>BRCA</i> mutation prevalence studies in breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Armstrong</LastName>
                    <ForeName>Nigel</ForeName>
                    <Initials>N</Initials>
                    <Identifier Source="ORCID">0000-0002-7443-4798</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Health Economics, Kleijnen Systematic Reviews Ltd., York YO19 6FD, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ryder</LastName>
                    <ForeName>Steve</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">0000-0003-1177-416X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Health Economics, Kleijnen Systematic Reviews Ltd., York YO19 6FD, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forbes</LastName>
                    <ForeName>Carol</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">0000-0001-6273-8455</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Systematic Reviews, Kleijnen Systematic Reviews Ltd., York YO19 6FD, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ross</LastName>
                    <ForeName>Janine</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">0000-0002-4763-2078</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Information, Kleijnen Systematic Reviews Ltd ., York YO19 6FD, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quek</LastName>
                    <ForeName>Ruben Gw</ForeName>
                    <Initials>RG</Initials>
                    <Identifier Source="ORCID">0000-0001-9602-3239</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Health Economics &amp; Outcomes Research, Pfizer Inc., San Francisco, CA 94105, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Clin Epidemiol</MedlineTA>
            <NlmUniqueID>101531700</NlmUniqueID>
            <ISSNLinking>1179-1349</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA1</Keyword>
            <Keyword MajorTopicYN="N">BRCA2</Keyword>
            <Keyword MajorTopicYN="N">chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">prevalence</Keyword>
            <Keyword MajorTopicYN="N">systematic review</Keyword>
        </KeywordList>
        <CoiStatement>NA, SR, CF, and JR are employees of Kleijnen Systematic Reviews Ltd., who were paid consultants to Pfizer in connection with the development of this manuscript. RGWQ is an employee of and owns stocks from Pfizer Inc. The authors report no other conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31372057</ArticleId>
            <ArticleId IdType="doi">10.2147/CLEP.S206949</ArticleId>
            <ArticleId IdType="pii">206949</ArticleId>
            <ArticleId IdType="pmc">PMC6628947</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31365755</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>07</Month>
            <Day>31</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">0890-9091</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>33</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jul</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncology (Williston Park, N.Y.)</Title>
                <ISOAbbreviation>Oncology (Williston Park, N.Y.)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">629388</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Saleh</LastName>
                    <ForeName>Naveed</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Copur</LastName>
                    <ForeName>Mehmet Sitki</ForeName>
                    <Initials>MS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncology (Williston Park)</MedlineTA>
            <NlmUniqueID>8712059</NlmUniqueID>
            <ISSNLinking>0890-9091</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31365755</ArticleId>
            <ArticleId IdType="pii">629388</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">31362334</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1648-9144</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>55</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jul</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Medicina (Kaunas, Lithuania)</Title>
                <ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E415</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina55080415</ELocationID>
            <Abstract>
                <AbstractText>Women carrying a BRCA mutation have an increased risk of developing breast and ovarian cancer. The most effective strategy to reduce this risk is the bilateral salpingo-oophorectomy, with or without additional risk-reducing mastectomy. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is recommended between age 35 and 40 and between age 40 and 45 years for women carriers of BRCA1 and BRCA2 mutations, respectively. Consequently, most BRCA mutation carriers undergo this procedure prior to a natural menopause and develop an anticipated lack of hormones. This condition has a detrimental impact on various systems, affecting both the quality of life and longevity; in particular, women carrying BRCA1 mutation, who are likely to have surgery earlier as compared to BRCA2. Hormonal replacement therapy (HRT) is the only effective strategy able to significantly compensate the hormonal deprivation and counteract menopausal symptoms, both in spontaneous and surgical menopause. Although recent evidence suggests that HRT does not diminish the protective effect of RRBSO in BRCA mutation carriers, concerns regarding the safety of estrogen and progesterone intake reduce the use in this setting. Furthermore, there is strong data demonstrating that the use of estrogen alone after RRBSO does not increase the risk of breast cancer among women with a BRCA1 mutation. The additional progesterone intake, mandatory for the protection of the endometrium during HRT, warrants further studies. However, when hysterectomy is performed at the time of RRBSO, the indication of progesterone addition decays and consequently its potential effect on breast cancer risk. Similarly, in patients conserving the uterus but undergoing risk-reducing mastectomy, the addition of progesterone should not raise significant concerns for breast cancer risk anymore. Therefore, BRCA mutation carriers require careful counselling about the scenarios following their RRBSO, menopausal symptoms or the fear associated with HRT use.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gasparri</LastName>
                    <ForeName>Maria Luisa</ForeName>
                    <Initials>ML</Initials>
                    <Identifier Source="ORCID">0000-0002-9482-9527</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Breast Surgery Unit, San Raffaele University Hospital, via Olgettina 60, 20132 Milan, Italy. gasparri.marialuisa@hsr.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taghavi</LastName>
                    <ForeName>Katayoun</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fiacco</LastName>
                    <ForeName>Enrico</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Surgery Unit, San Raffaele University Hospital, via Olgettina 60, 20132 Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zuber</LastName>
                    <ForeName>Veronica</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Surgery Unit, San Raffaele University Hospital, via Olgettina 60, 20132 Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Di Micco</LastName>
                    <ForeName>Rosa</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Surgery Unit, San Raffaele University Hospital, via Olgettina 60, 20132 Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical medicine and Surgery, University of Naples Federico II, Corso Umberto I 40, 80138 Naples, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gazzetta</LastName>
                    <ForeName>Guglielmo</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Surgery Unit, San Raffaele University Hospital, via Olgettina 60, 20132 Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valentini</LastName>
                    <ForeName>Alice</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Surgery Unit, San Raffaele University Hospital, via Olgettina 60, 20132 Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mueller</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Hospital of Bern, Friedbühlstrasse 19, 3010 Bern, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Papadia</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University of the Italian Switzerland (USI) and Ente Ospedaliere Cantonale (EOC), Via Tesserete 46, 6900 Lugano, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gentilini</LastName>
                    <ForeName>Oreste D</ForeName>
                    <Initials>OD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Surgery Unit, San Raffaele University Hospital, via Olgettina 60, 20132 Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016421">Editorial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Medicina (Kaunas)</MedlineTA>
            <NlmUniqueID>9425208</NlmUniqueID>
            <ISSNLinking>1010-660X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA mutation carriers</Keyword>
            <Keyword MajorTopicYN="N">bilateral salpingo-oophorectomy</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">hormonal replacement therapy</Keyword>
            <Keyword MajorTopicYN="N">menopause</Keyword>
            <Keyword MajorTopicYN="N">ovarian cancer</Keyword>
            <Keyword MajorTopicYN="N">risk reducing surgery</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31362334</ArticleId>
            <ArticleId IdType="pii">medicina55080415</ArticleId>
            <ArticleId IdType="doi">10.3390/medicina55080415</ArticleId>
            <ArticleId IdType="pmc">PMC6722681</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>